Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2186899,maximum concentration (Cmax),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],285,748,DB00205,Pyrimethamine
,2186899,maximum concentration (Cmax),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],151,749,DB00205,Pyrimethamine
,2186899,minimum concentration (Cmin),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],125,750,DB00205,Pyrimethamine
,2186899,minimum concentration (Cmin),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],31,751,DB00205,Pyrimethamine
,2186899,elimination half-life (t1/2),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),h,23.3,752,DB00205,Pyrimethamine
,2186899,elimination half-life (t1/2),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),h,18.3,753,DB00205,Pyrimethamine
,2186899,plasma clearance (Cl),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [h·kg],0.032,754,DB00205,Pyrimethamine
,2186899,plasma clearance (Cl),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [h·kg],1.27,755,DB00205,Pyrimethamine
,2186899,apparent volume of distribution (Vss),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [kg],1.05,756,DB00205,Pyrimethamine
,2186899,apparent volume of distribution (Vss),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [kg],33.32,757,DB00205,Pyrimethamine
,2186899,Cmax,"The Cmax, Cmin and t1/2 of CYCLO were 56 ng/ml, 17 ng/ml and 15.0 h, respectively.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],56,758,DB00205,Pyrimethamine
,2186899,Cmin,"The Cmax, Cmin and t1/2 of CYCLO were 56 ng/ml, 17 ng/ml and 15.0 h, respectively.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],17,759,DB00205,Pyrimethamine
,2186899,t1/2,"The Cmax, Cmin and t1/2 of CYCLO were 56 ng/ml, 17 ng/ml and 15.0 h, respectively.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),h,15.0,760,DB00205,Pyrimethamine
,2785812,Time to peak concentrations,"Time to peak concentrations (mean +/- s.d. for mefloquine (5.70 +/- 0.95 h), sulphadoxine (3.75 +/- 2.03 h) and pyrimethamine (3.30 +/- 1.98 h) were similar to those observed by others after administration of the single compounds.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,5.70,5181,DB00205,Pyrimethamine
,2785812,Time to peak concentrations,"Time to peak concentrations (mean +/- s.d. for mefloquine (5.70 +/- 0.95 h), sulphadoxine (3.75 +/- 2.03 h) and pyrimethamine (3.30 +/- 1.98 h) were similar to those observed by others after administration of the single compounds.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,3.75,5182,DB00205,Pyrimethamine
,2785812,Time to peak concentrations,"Time to peak concentrations (mean +/- s.d. for mefloquine (5.70 +/- 0.95 h), sulphadoxine (3.75 +/- 2.03 h) and pyrimethamine (3.30 +/- 1.98 h) were similar to those observed by others after administration of the single compounds.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,3.30,5183,DB00205,Pyrimethamine
,2785812,t1/2s,"The t1/2s for mefloquine, sulphadoxine and pyrimethamine were 387 +/- 98 h, 255 +/- 61 h and 114 +/- 42 h, respectively.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,387,5184,DB00205,Pyrimethamine
,2785812,t1/2s,"The t1/2s for mefloquine, sulphadoxine and pyrimethamine were 387 +/- 98 h, 255 +/- 61 h and 114 +/- 42 h, respectively.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,255,5185,DB00205,Pyrimethamine
,2785812,t1/2s,"The t1/2s for mefloquine, sulphadoxine and pyrimethamine were 387 +/- 98 h, 255 +/- 61 h and 114 +/- 42 h, respectively.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,114,5186,DB00205,Pyrimethamine
,16127028,maximum sulfadoxine,"When patients with ACPR and TF were compared, mean values were similar for the day 3 blood pyrimethamine (205 ng/ml versus 172 ng/ml; P = 0.25) and estimated maximum sulfadoxine (79 +/- 6.52 versus 69 +/- 6.27 mug/ml; P = 0.60) concentrations, for sulfadoxine terminal-phase elimination half-lives (7.15 versus 6.41 days; P = 0.42), and for the extents of sulfadoxine absorption (areas under the concentration-time curve of 932 +/- 100 versus 888 +/- 78.9 mug day ml(-1); P = 0.72).",Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127028/),[μg] / [ml],79,5974,DB00205,Pyrimethamine
,16127028,maximum sulfadoxine,"When patients with ACPR and TF were compared, mean values were similar for the day 3 blood pyrimethamine (205 ng/ml versus 172 ng/ml; P = 0.25) and estimated maximum sulfadoxine (79 +/- 6.52 versus 69 +/- 6.27 mug/ml; P = 0.60) concentrations, for sulfadoxine terminal-phase elimination half-lives (7.15 versus 6.41 days; P = 0.42), and for the extents of sulfadoxine absorption (areas under the concentration-time curve of 932 +/- 100 versus 888 +/- 78.9 mug day ml(-1); P = 0.72).",Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127028/),[μg] / [ml],69,5975,DB00205,Pyrimethamine
,16127028,terminal-phase elimination half-lives,"When patients with ACPR and TF were compared, mean values were similar for the day 3 blood pyrimethamine (205 ng/ml versus 172 ng/ml; P = 0.25) and estimated maximum sulfadoxine (79 +/- 6.52 versus 69 +/- 6.27 mug/ml; P = 0.60) concentrations, for sulfadoxine terminal-phase elimination half-lives (7.15 versus 6.41 days; P = 0.42), and for the extents of sulfadoxine absorption (areas under the concentration-time curve of 932 +/- 100 versus 888 +/- 78.9 mug day ml(-1); P = 0.72).",Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127028/),d,7.15,5976,DB00205,Pyrimethamine
,16127028,terminal-phase elimination half-lives,"When patients with ACPR and TF were compared, mean values were similar for the day 3 blood pyrimethamine (205 ng/ml versus 172 ng/ml; P = 0.25) and estimated maximum sulfadoxine (79 +/- 6.52 versus 69 +/- 6.27 mug/ml; P = 0.60) concentrations, for sulfadoxine terminal-phase elimination half-lives (7.15 versus 6.41 days; P = 0.42), and for the extents of sulfadoxine absorption (areas under the concentration-time curve of 932 +/- 100 versus 888 +/- 78.9 mug day ml(-1); P = 0.72).",Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127028/),d,6.41,5977,DB00205,Pyrimethamine
,16127028,areas under the concentration-time curve,"When patients with ACPR and TF were compared, mean values were similar for the day 3 blood pyrimethamine (205 ng/ml versus 172 ng/ml; P = 0.25) and estimated maximum sulfadoxine (79 +/- 6.52 versus 69 +/- 6.27 mug/ml; P = 0.60) concentrations, for sulfadoxine terminal-phase elimination half-lives (7.15 versus 6.41 days; P = 0.42), and for the extents of sulfadoxine absorption (areas under the concentration-time curve of 932 +/- 100 versus 888 +/- 78.9 mug day ml(-1); P = 0.72).",Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127028/),[d·μg] / [ml],932,5978,DB00205,Pyrimethamine
,16127028,areas under the concentration-time curve,"When patients with ACPR and TF were compared, mean values were similar for the day 3 blood pyrimethamine (205 ng/ml versus 172 ng/ml; P = 0.25) and estimated maximum sulfadoxine (79 +/- 6.52 versus 69 +/- 6.27 mug/ml; P = 0.60) concentrations, for sulfadoxine terminal-phase elimination half-lives (7.15 versus 6.41 days; P = 0.42), and for the extents of sulfadoxine absorption (areas under the concentration-time curve of 932 +/- 100 versus 888 +/- 78.9 mug day ml(-1); P = 0.72).",Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127028/),[d·μg] / [ml],888,5979,DB00205,Pyrimethamine
,20166428,AUC,"The main disposition parameters to AS+AQ were: for DHA, AUC = 632 +/- 475 ng h/ml and Cmax = 432 +/- 325 ng/ml, and for MdAQ = 14268 +/- 4114 ng h/ml and Cmax = 336 +/- 225 ng/ml (mean +/- standard deviation).",Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166428/),[h·ng] / [ml],632,6017,DB00205,Pyrimethamine
,20166428,Cmax,"The main disposition parameters to AS+AQ were: for DHA, AUC = 632 +/- 475 ng h/ml and Cmax = 432 +/- 325 ng/ml, and for MdAQ = 14268 +/- 4114 ng h/ml and Cmax = 336 +/- 225 ng/ml (mean +/- standard deviation).",Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166428/),[ng] / [ml],432,6018,DB00205,Pyrimethamine
,20166428,Cmax,"The main disposition parameters to AS+AQ were: for DHA, AUC = 632 +/- 475 ng h/ml and Cmax = 432 +/- 325 ng/ml, and for MdAQ = 14268 +/- 4114 ng h/ml and Cmax = 336 +/- 225 ng/ml (mean +/- standard deviation).",Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166428/),[ng] / [ml],336,6019,DB00205,Pyrimethamine
,16725391,run time,The run time was 4.5 min and the weighted (1/x2) calibration curves were linear over a range of 0.78-400 ng ml-1.,"Simultaneous quantification of alpha-/beta-diastereomers of arteether, sulphadoxine and pyrimethamine: a promising anti-relapse antimalarial therapeutic combination, by liquid chromatography tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16725391/),min,4.5,9674,DB00205,Pyrimethamine
,7957448,clearance time,No statistical difference was noted for clinical response except the gametocyte clearance time was shorter in children given MSP plus primaquine (7 +/- 2.7 days) than the children given MSP alone (21.9 +/- 4.4 days) (P < 0.01).,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,7,23703,DB00205,Pyrimethamine
,7957448,clearance time,No statistical difference was noted for clinical response except the gametocyte clearance time was shorter in children given MSP plus primaquine (7 +/- 2.7 days) than the children given MSP alone (21.9 +/- 4.4 days) (P < 0.01).,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,21.9,23704,DB00205,Pyrimethamine
,7957448,Cmax,Mean Cmax was 7.4 +/- 5.2 h in group I and 6.6 +/- 7.0 h in group II.,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),h,7.4,23705,DB00205,Pyrimethamine
,7957448,Cmax,Mean Cmax was 7.4 +/- 5.2 h in group I and 6.6 +/- 7.0 h in group II.,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),h,6.6,23706,DB00205,Pyrimethamine
,7957448,t1/2,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,9.8,23707,DB00205,Pyrimethamine
,7957448,Cl/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[ml] / [kg·min],0.43,23708,DB00205,Pyrimethamine
,7957448,Cl/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,9.3,23709,DB00205,Pyrimethamine
,7957448,Cl/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[ml] / [kg·min],0.41,23710,DB00205,Pyrimethamine
,7957448,Vd/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[l] / [kg],8.84,23711,DB00205,Pyrimethamine
,7957448,Vd/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[l] / [kg],8.91,23712,DB00205,Pyrimethamine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,2.6,25394,DB00205,Pyrimethamine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,68,25395,DB00205,Pyrimethamine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,40,25396,DB00205,Pyrimethamine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,60,25397,DB00205,Pyrimethamine
,28499878,Km,"Moreover, the uptake of sulpiride by human hepatocytes was diminished by tetraethylammonium, and saturable with Km of 18 μM.","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,18,25398,DB00205,Pyrimethamine
,32482623,half-life,"CPI-d8 has a half-life and bioavailability of 7.6 hours and 3.2%, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h,7.6,26063,DB00205,Pyrimethamine
,32482623,bioavailability,"CPI-d8 has a half-life and bioavailability of 7.6 hours and 3.2%, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),%,3.2,26064,DB00205,Pyrimethamine
,32482623,maximum blood concentrations (C max),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,0.19,26065,DB00205,Pyrimethamine
,32482623,maximum blood concentrations (C max),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,2.5,26066,DB00205,Pyrimethamine
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,3.8,26067,DB00205,Pyrimethamine
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,2.7,26068,DB00205,Pyrimethamine
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,10.5,26069,DB00205,Pyrimethamine
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,26.6,26070,DB00205,Pyrimethamine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1.8,26071,DB00205,Pyrimethamine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,6.2,26072,DB00205,Pyrimethamine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,10.5,26073,DB00205,Pyrimethamine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1,26074,DB00205,Pyrimethamine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1.4,26075,DB00205,Pyrimethamine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,4.4,26076,DB00205,Pyrimethamine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,4.6,26077,DB00205,Pyrimethamine
,19858250,areas under the plasma concentration-time curve (AUC(0-infinity)),"The areas under the plasma concentration-time curve (AUC(0-infinity)) (28.7 and 31.8 mg.h liter(-1) for pregnant and nonpregnant subjects, respectively) were consistent with the results of previous studies, but the estimated terminal elimination half-lives (78 and 77 h, respectively) were generally longer.",Pharmacokinetic properties of azithromycin in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858250/),[h·mg] / [liter],28.7,32896,DB00205,Pyrimethamine
,19858250,areas under the plasma concentration-time curve (AUC(0-infinity)),"The areas under the plasma concentration-time curve (AUC(0-infinity)) (28.7 and 31.8 mg.h liter(-1) for pregnant and nonpregnant subjects, respectively) were consistent with the results of previous studies, but the estimated terminal elimination half-lives (78 and 77 h, respectively) were generally longer.",Pharmacokinetic properties of azithromycin in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858250/),[h·mg] / [liter],31.8,32897,DB00205,Pyrimethamine
,19858250,terminal elimination half-lives,"The areas under the plasma concentration-time curve (AUC(0-infinity)) (28.7 and 31.8 mg.h liter(-1) for pregnant and nonpregnant subjects, respectively) were consistent with the results of previous studies, but the estimated terminal elimination half-lives (78 and 77 h, respectively) were generally longer.",Pharmacokinetic properties of azithromycin in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858250/),h,78,32898,DB00205,Pyrimethamine
,19858250,terminal elimination half-lives,"The areas under the plasma concentration-time curve (AUC(0-infinity)) (28.7 and 31.8 mg.h liter(-1) for pregnant and nonpregnant subjects, respectively) were consistent with the results of previous studies, but the estimated terminal elimination half-lives (78 and 77 h, respectively) were generally longer.",Pharmacokinetic properties of azithromycin in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858250/),h,77,32899,DB00205,Pyrimethamine
,28710808,AUCratio,"Antiretroviral-mediated DDIs (efavirenz and ritonavir) had moderate effects on piperaquine during different gestational weeks with a predicted AUCratio in the range 0.56-0.8 and 1.64-1.79 for efavirenz and ritonavir, respectively, over GW 10-40, with a reduction in circulating human serum albumin significantly reducing the number of subjects attaining the day 7 (post-dose) therapeutic efficacy concentrations under both efavirenz and ritonavir DDIs.",The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710808/),,0.56-0.8,34321,DB00205,Pyrimethamine
,28710808,AUCratio,"Antiretroviral-mediated DDIs (efavirenz and ritonavir) had moderate effects on piperaquine during different gestational weeks with a predicted AUCratio in the range 0.56-0.8 and 1.64-1.79 for efavirenz and ritonavir, respectively, over GW 10-40, with a reduction in circulating human serum albumin significantly reducing the number of subjects attaining the day 7 (post-dose) therapeutic efficacy concentrations under both efavirenz and ritonavir DDIs.",The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710808/),,1.64-1.79,34322,DB00205,Pyrimethamine
,3307789,t1/2 beta,"Perfusate half-life of pyrimethamine was increased in livers from M.I. rats (t1/2 beta control group = 56 +/- 11 min vs M.I. group = 101 +/- 12, P less than 0.01), reflecting a decrease in hepatic clearance (3.6 +/- 1.1 ml/min vs 1.9 +/- 0.5 ml/min, P less than 0.01).",Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307789/),min,56,34358,DB00205,Pyrimethamine
,3307789,t1/2 beta,"Perfusate half-life of pyrimethamine was increased in livers from M.I. rats (t1/2 beta control group = 56 +/- 11 min vs M.I. group = 101 +/- 12, P less than 0.01), reflecting a decrease in hepatic clearance (3.6 +/- 1.1 ml/min vs 1.9 +/- 0.5 ml/min, P less than 0.01).",Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307789/),,101,34359,DB00205,Pyrimethamine
,3307789,hepatic clearance,"Perfusate half-life of pyrimethamine was increased in livers from M.I. rats (t1/2 beta control group = 56 +/- 11 min vs M.I. group = 101 +/- 12, P less than 0.01), reflecting a decrease in hepatic clearance (3.6 +/- 1.1 ml/min vs 1.9 +/- 0.5 ml/min, P less than 0.01).",Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307789/),[ml] / [min],3.6,34360,DB00205,Pyrimethamine
,3307789,hepatic clearance,"Perfusate half-life of pyrimethamine was increased in livers from M.I. rats (t1/2 beta control group = 56 +/- 11 min vs M.I. group = 101 +/- 12, P less than 0.01), reflecting a decrease in hepatic clearance (3.6 +/- 1.1 ml/min vs 1.9 +/- 0.5 ml/min, P less than 0.01).",Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307789/),[ml] / [min],1.9,34361,DB00205,Pyrimethamine
,3307789,Intrahepatic concentration of unchanged,"Intrahepatic concentration of unchanged drug at 3 hr was 4-5-fold greater in livers from infected rats (control group = 4725 +/- 2287 ng/ml vs M.I. group = 22,324 +/- 6824 ng/ml), while liver: perfusate concentration ratios were not significantly different (control group = 30.8 +/- 24.1 vs M.I. group = 35.6 +/- 20.3).",Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307789/),[ng] / [ml],4725,34362,DB00205,Pyrimethamine
,3307789,Intrahepatic concentration of unchanged,"Intrahepatic concentration of unchanged drug at 3 hr was 4-5-fold greater in livers from infected rats (control group = 4725 +/- 2287 ng/ml vs M.I. group = 22,324 +/- 6824 ng/ml), while liver: perfusate concentration ratios were not significantly different (control group = 30.8 +/- 24.1 vs M.I. group = 35.6 +/- 20.3).",Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307789/),[ng] / [ml],"22,324",34363,DB00205,Pyrimethamine
,3307789,concentration ratios,"Intrahepatic concentration of unchanged drug at 3 hr was 4-5-fold greater in livers from infected rats (control group = 4725 +/- 2287 ng/ml vs M.I. group = 22,324 +/- 6824 ng/ml), while liver: perfusate concentration ratios were not significantly different (control group = 30.8 +/- 24.1 vs M.I. group = 35.6 +/- 20.3).",Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307789/),,30.8,34364,DB00205,Pyrimethamine
,3307789,concentration ratios,"Intrahepatic concentration of unchanged drug at 3 hr was 4-5-fold greater in livers from infected rats (control group = 4725 +/- 2287 ng/ml vs M.I. group = 22,324 +/- 6824 ng/ml), while liver: perfusate concentration ratios were not significantly different (control group = 30.8 +/- 24.1 vs M.I. group = 35.6 +/- 20.3).",Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307789/),,35.6,34365,DB00205,Pyrimethamine
,8491823,flow-rate,"The mobile phase, consisting of acetonitrile-methanol-phosphate buffer (2:1:7, v/v/v), was delivered at a flow-rate of 1.2 ml/min, and ultraviolet absorbance was monitored at 286 nm.","Simultaneous determination of dapsone, monoacetyldapsone and pyrimethamine in whole blood and plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491823/),[ml] / [min],1.2,34521,DB00205,Pyrimethamine
,8619446,detection limits,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],3,36204,DB00205,Pyrimethamine
,8619446,detection limits,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],1,36205,DB00205,Pyrimethamine
,8619446,detection limits,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],5,36206,DB00205,Pyrimethamine
,8619446,signal-to-noise ratio,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],3,36207,DB00205,Pyrimethamine
,8619446,signal-to-noise ratio,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],1,36208,DB00205,Pyrimethamine
,8619446,signal-to-noise ratio,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],5,36209,DB00205,Pyrimethamine
>,8619446,Recoveries,Recoveries of the analytes and the internal standard (pyrimethamine) were > 62% from plasma and > 77% from urine.,"Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),%,62,36210,DB00205,Pyrimethamine
>,8619446,Recoveries,Recoveries of the analytes and the internal standard (pyrimethamine) were > 62% from plasma and > 77% from urine.,"Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),%,77,36211,DB00205,Pyrimethamine
,15151519,CL,"Typical CL and V estimates (95% confidence interval), for a child weighing 11 kg were 5.50 (5.28, 5.73) l day(-1) and 36 (33, 39) l for PYR and 0.26 (0.25, 0.27) l day(-1) and 2.1 (1.9, 2.3) l for SDX.",Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151519/),[l] / [day],5.50,37113,DB00205,Pyrimethamine
,15151519,V,"Typical CL and V estimates (95% confidence interval), for a child weighing 11 kg were 5.50 (5.28, 5.73) l day(-1) and 36 (33, 39) l for PYR and 0.26 (0.25, 0.27) l day(-1) and 2.1 (1.9, 2.3) l for SDX.",Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151519/),l,36,37114,DB00205,Pyrimethamine
,15151519,V,"Typical CL and V estimates (95% confidence interval), for a child weighing 11 kg were 5.50 (5.28, 5.73) l day(-1) and 36 (33, 39) l for PYR and 0.26 (0.25, 0.27) l day(-1) and 2.1 (1.9, 2.3) l for SDX.",Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151519/),l,2.1,37115,DB00205,Pyrimethamine
,15151519,plasma half-lives,"For BW between 3.5 and 60 kg, plasma half-lives were predicted to vary from 4.0 to 5.2 days for PYR, and from 5.0 to 7.5 days for SDX.",Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151519/),d,4.0 to 5.2,37116,DB00205,Pyrimethamine
,15151519,plasma half-lives,"For BW between 3.5 and 60 kg, plasma half-lives were predicted to vary from 4.0 to 5.2 days for PYR, and from 5.0 to 7.5 days for SDX.",Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151519/),d,5.0 to 7.5,37117,DB00205,Pyrimethamine
,33046062,IC50,The compound had been shown to inhibit Plasmodium HDAC with IC50 of 31 nM and human HDAC with IC50 of 3 nM.,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),nM,31,37625,DB00205,Pyrimethamine
,33046062,IC50,The compound had been shown to inhibit Plasmodium HDAC with IC50 of 31 nM and human HDAC with IC50 of 3 nM.,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),nM,3,37626,DB00205,Pyrimethamine
,33046062,IC50,The IC50 obtained for P. falciparum in asexual blood-stage assay was 42 nM.,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),nM,42,37627,DB00205,Pyrimethamine
,33046062,IC50,"The selected compound was also active against gametocytes, indicating a potential for transmission control: IC50 values being 190 nM for male and > 5 µM for female gametocytes.","Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),nM,190,37628,DB00205,Pyrimethamine
>,33046062,IC50,"The selected compound was also active against gametocytes, indicating a potential for transmission control: IC50 values being 190 nM for male and > 5 µM for female gametocytes.","Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),μM,5,37629,DB00205,Pyrimethamine
>,33046062,IC50,"FNDR-20123 is a stable candidate in human/mouse/rat liver microsomes (> 75% remaining post 2-h incubation), exhibits low plasma protein binding (57% in humans) with no human Ether-à-go-go-Related Gene (hERG) liability (> 100 µM), and does not inhibit any of the cytochrome P450 (CYP) isoforms tested (IC50 > 25 µM).","Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),μM,25,37630,DB00205,Pyrimethamine
,33046062,Cmax,The oral pharmacokinetics in rats at 100 mg/kg body weight shows good exposures (Cmax = 1.1 µM) and half-life (T1/2 = 5.5 h).,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),μM,1.1,37631,DB00205,Pyrimethamine
,33046062,half-life (T1/2,The oral pharmacokinetics in rats at 100 mg/kg body weight shows good exposures (Cmax = 1.1 µM) and half-life (T1/2 = 5.5 h).,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),h,5.5,37632,DB00205,Pyrimethamine
,31950646,half-life,"After absorption, pyrimethamine was eliminated, with a mean half-life of 122.8 hours in Japanese subjects and 99.5 hours in European subjects.","Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),h,122.8,45851,DB00205,Pyrimethamine
,31950646,half-life,"After absorption, pyrimethamine was eliminated, with a mean half-life of 122.8 hours in Japanese subjects and 99.5 hours in European subjects.","Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),h,99.5,45852,DB00205,Pyrimethamine
,31950646,Cmax,The mean Cmax and AUC0-t were 433.8 ng/mL and 59.63 µg·h/mL in Japanese subjects and 372.7 ng/mL and 42.83 µg·h/mL in European subjects.,"Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),[ng] / [ml],433.8,45853,DB00205,Pyrimethamine
,31950646,Cmax,The mean Cmax and AUC0-t were 433.8 ng/mL and 59.63 µg·h/mL in Japanese subjects and 372.7 ng/mL and 42.83 µg·h/mL in European subjects.,"Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),[ng] / [ml],372.7,45854,DB00205,Pyrimethamine
,31950646,AUC0-t,The mean Cmax and AUC0-t were 433.8 ng/mL and 59.63 µg·h/mL in Japanese subjects and 372.7 ng/mL and 42.83 µg·h/mL in European subjects.,"Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),[h·μg] / [ml],59.63,45855,DB00205,Pyrimethamine
,31950646,AUC0-t,The mean Cmax and AUC0-t were 433.8 ng/mL and 59.63 µg·h/mL in Japanese subjects and 372.7 ng/mL and 42.83 µg·h/mL in European subjects.,"Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),[h·μg] / [ml],42.83,45856,DB00205,Pyrimethamine
,1820893,area under the plasma concentration-time curve (AUC0-inf),The area under the plasma concentration-time curve (AUC0-inf) was 56.8 18.4 h.mg/ml.,Pharmacokinetics of pyrimethamine in healthy young volunteers using a new solid phase extraction/HPLC method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820893/),[h·mg] / [ml],56.8,52210,DB00205,Pyrimethamine
,1820893,volume of distribution Vd,The volume of distribution Vd was: 2.42 1.25 l/kg and the total clearance: 15.55 4.48 ml/h/kg.,Pharmacokinetics of pyrimethamine in healthy young volunteers using a new solid phase extraction/HPLC method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820893/),[l] / [kg],2.42,52211,DB00205,Pyrimethamine
,1820893,volume of distribution Vd,The volume of distribution Vd was: 2.42 1.25 l/kg and the total clearance: 15.55 4.48 ml/h/kg.,Pharmacokinetics of pyrimethamine in healthy young volunteers using a new solid phase extraction/HPLC method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820893/),[l] / [kg],1.25,52212,DB00205,Pyrimethamine
,1820893,total clearance,The volume of distribution Vd was: 2.42 1.25 l/kg and the total clearance: 15.55 4.48 ml/h/kg.,Pharmacokinetics of pyrimethamine in healthy young volunteers using a new solid phase extraction/HPLC method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820893/),[ml] / [h·kg],15.55,52213,DB00205,Pyrimethamine
,1820893,total clearance,The volume of distribution Vd was: 2.42 1.25 l/kg and the total clearance: 15.55 4.48 ml/h/kg.,Pharmacokinetics of pyrimethamine in healthy young volunteers using a new solid phase extraction/HPLC method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820893/),[ml] / [h·kg],4.48,52214,DB00205,Pyrimethamine
,2208897,half-life,These have shown in healthy volunteers that mefloquine is absorbed with a half-life of 1 to 4 hours and a time to peak concentration of 7 to 24 hours (median 16.7 hours).,Clinical pharmacokinetics of mefloquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),h,1 to 4,53513,DB00205,Pyrimethamine
,2208897,time to peak concentration,These have shown in healthy volunteers that mefloquine is absorbed with a half-life of 1 to 4 hours and a time to peak concentration of 7 to 24 hours (median 16.7 hours).,Clinical pharmacokinetics of mefloquine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),h,7 to 24,53514,DB00205,Pyrimethamine
,2208897,time to peak concentration,These have shown in healthy volunteers that mefloquine is absorbed with a half-life of 1 to 4 hours and a time to peak concentration of 7 to 24 hours (median 16.7 hours).,Clinical pharmacokinetics of mefloquine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),h,16.7,53515,DB00205,Pyrimethamine
,2208897,peak blood concentrations,Mean peak blood concentrations have ranged between 50 and 110 (median 83) ng/ml/mg/kg.,Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],50 and 110,53516,DB00205,Pyrimethamine
,2208897,peak blood concentrations,Mean peak blood concentrations have ranged between 50 and 110 (median 83) ng/ml/mg/kg.,Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],83,53517,DB00205,Pyrimethamine
,2208897,total apparent volume of distribution (Vd/f),"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[l] / [kg],19.2,53518,DB00205,Pyrimethamine
,2208897,systemic clearance (CL/f),"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[l] / [h·kg],0.022 to 0.073,53519,DB00205,Pyrimethamine
,2208897,systemic clearance (CL/f),"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[l] / [h·kg],0.026,53520,DB00205,Pyrimethamine
,2208897,terminal elimination half-life,"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),d,13.8 to 40.9,53521,DB00205,Pyrimethamine
,2208897,terminal elimination half-life,"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),d,20,53522,DB00205,Pyrimethamine
,2208897,peak blood concentrations,"In uncomplicated falciparum malaria, peak blood concentrations are 2 to 3 times higher than those in healthy subjects ranging from 112 to 209 (median 144) ng/ml/mg/kg because of contraction in the total apparent volume of distribution.",Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],112 to 209,53523,DB00205,Pyrimethamine
,2208897,peak blood concentrations,"In uncomplicated falciparum malaria, peak blood concentrations are 2 to 3 times higher than those in healthy subjects ranging from 112 to 209 (median 144) ng/ml/mg/kg because of contraction in the total apparent volume of distribution.",Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],144,53524,DB00205,Pyrimethamine
exceeds,2208897,plasma protein binding,Mefloquine absorption appears to be reduced in severe falciparum malaria; plasma protein binding exceeds 98% in both healthy subjects and patients.,Clinical pharmacokinetics of mefloquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),%,98,53525,DB00205,Pyrimethamine
,25788349,T max,"In contrast to its plain and marketed formulation, pyrimethamine nanosuspension showed rapid onset of action (T max 0.5 h vs. 2 h).",Pyrimethamine nanosuspension with improved bioavailability: in vivo pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25788349/),h,0.5,64556,DB00205,Pyrimethamine
,25788349,T max,"In contrast to its plain and marketed formulation, pyrimethamine nanosuspension showed rapid onset of action (T max 0.5 h vs. 2 h).",Pyrimethamine nanosuspension with improved bioavailability: in vivo pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25788349/),h,2,64557,DB00205,Pyrimethamine
,21282434,area under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)),"The area under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)) was greater with the double dose versus the conventional dose of PYR (4,915 versus 2,844 μg/day/liter) and SDX (2,434 versus 1,460 mg/day/liter).",Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21282434/),[μg] / [d·l],"4,915",65423,DB00205,Pyrimethamine
,21282434,area under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)),"The area under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)) was greater with the double dose versus the conventional dose of PYR (4,915 versus 2,844 μg/day/liter) and SDX (2,434 versus 1,460 mg/day/liter).",Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21282434/),[μg] / [d·l],"2,844",65424,DB00205,Pyrimethamine
,21282434,area under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)),"The area under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)) was greater with the double dose versus the conventional dose of PYR (4,915 versus 2,844 μg/day/liter) and SDX (2,434 versus 1,460 mg/day/liter).",Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21282434/),[mg] / [d·l],"2,434",65425,DB00205,Pyrimethamine
,21282434,area under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)),"The area under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)) was greater with the double dose versus the conventional dose of PYR (4,915 versus 2,844 μg/day/liter) and SDX (2,434 versus 1,460 mg/day/liter).",Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21282434/),[mg] / [d·l],"1,460",65426,DB00205,Pyrimethamine
,21282434,Terminal elimination half-lives,"Terminal elimination half-lives (15.6 days for PYR, 9.1 days for SDX) were longer than previously reported.",Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21282434/),d,15.6,65427,DB00205,Pyrimethamine
,21282434,Terminal elimination half-lives,"Terminal elimination half-lives (15.6 days for PYR, 9.1 days for SDX) were longer than previously reported.",Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21282434/),d,9.1,65428,DB00205,Pyrimethamine
,9740261,terminal phase elimination half-life,"Elimination of pyrimethamine was however, a relatively slow process compared with artemether, and thus resulted in a long terminal phase elimination half-life (50-106 hours).",Pharmacokinetic interactions of artemether and pyrimethamine in healthy male Thais. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9740261/),h,50-106,75434,DB00205,Pyrimethamine
,9740261,Cmax,"In contrast, coadministration of artemether resulted in significantly increased Cmax (medians of 818 vs 1,180 ng/ml) and contracted the apparent volume of distribution (medians of 3 vs 2.56 l/kg) of pyrimethamine.",Pharmacokinetic interactions of artemether and pyrimethamine in healthy male Thais. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9740261/),[ng] / [ml],818,75435,DB00205,Pyrimethamine
,9740261,Cmax,"In contrast, coadministration of artemether resulted in significantly increased Cmax (medians of 818 vs 1,180 ng/ml) and contracted the apparent volume of distribution (medians of 3 vs 2.56 l/kg) of pyrimethamine.",Pharmacokinetic interactions of artemether and pyrimethamine in healthy male Thais. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9740261/),[ng] / [ml],"1,180",75436,DB00205,Pyrimethamine
,9740261,apparent volume of distribution,"In contrast, coadministration of artemether resulted in significantly increased Cmax (medians of 818 vs 1,180 ng/ml) and contracted the apparent volume of distribution (medians of 3 vs 2.56 l/kg) of pyrimethamine.",Pharmacokinetic interactions of artemether and pyrimethamine in healthy male Thais. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9740261/),[l] / [kg],3,75437,DB00205,Pyrimethamine
,9740261,apparent volume of distribution,"In contrast, coadministration of artemether resulted in significantly increased Cmax (medians of 818 vs 1,180 ng/ml) and contracted the apparent volume of distribution (medians of 3 vs 2.56 l/kg) of pyrimethamine.",Pharmacokinetic interactions of artemether and pyrimethamine in healthy male Thais. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9740261/),[l] / [kg],2.56,75438,DB00205,Pyrimethamine
,31511257,renal clearance,"The renal clearance (46.9 ± 4.9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16.6 ± 2.6 and 24.3 ± 0.6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],46.9,76468,DB00205,Pyrimethamine
,31511257,renal clearance,"The renal clearance (46.9 ± 4.9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16.6 ± 2.6 and 24.3 ± 0.6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],16.6,76469,DB00205,Pyrimethamine
,31511257,renal clearance,"The renal clearance (46.9 ± 4.9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16.6 ± 2.6 and 24.3 ± 0.6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],24.3,76470,DB00205,Pyrimethamine
,31511257,renal clearance,"The renal clearance of m1A in younger (21-45 year old) and older (65-79 year old) volunteers (244 ± 58 and 169 ± 22 ml/min per kilogram, respectively) was about 2-fold higher than the creatinine clearance.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],244,76471,DB00205,Pyrimethamine
,31511257,renal clearance,"The renal clearance of m1A in younger (21-45 year old) and older (65-79 year old) volunteers (244 ± 58 and 169 ± 22 ml/min per kilogram, respectively) was about 2-fold higher than the creatinine clearance.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],169,76472,DB00205,Pyrimethamine
,7332733,peak level,"3 At an oral dose of 65 mg/m2 without leucovorin, a peak level of 0.6 microgram/ml and an AUC of 52 micrograms ml-1 h produced significant leukopenia and thrombocytopenia.","Kinetics of metoprine, a lipid-soluble antifolate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[μg] / [ml],0.6,79316,DB00205,Pyrimethamine
,7332733,AUC,"3 At an oral dose of 65 mg/m2 without leucovorin, a peak level of 0.6 microgram/ml and an AUC of 52 micrograms ml-1 h produced significant leukopenia and thrombocytopenia.","Kinetics of metoprine, a lipid-soluble antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[h·μg] / [ml],52,79317,DB00205,Pyrimethamine
,7332733,peak serum level,This patient also had the highest peak serum level (2.8 micrograms/ml) and AUC (228 micrograms ml-1 h).,"Kinetics of metoprine, a lipid-soluble antifolate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[μg] / [ml],2.8,79318,DB00205,Pyrimethamine
,7332733,AUC,This patient also had the highest peak serum level (2.8 micrograms/ml) and AUC (228 micrograms ml-1 h).,"Kinetics of metoprine, a lipid-soluble antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[h·μg] / [ml],228,79319,DB00205,Pyrimethamine
,7332733,peak levels,"5 One partial response and one minor regression were observed in the studied patients; these two patients had the 175 mg/m2 dose, highest peak levels (2.4 and 2.8 micrograms/ml) and highest AUCs (197 and 228 micrograms ml-1 h).","Kinetics of metoprine, a lipid-soluble antifolate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[μg] / [ml],2.4,79320,DB00205,Pyrimethamine
,7332733,peak levels,"5 One partial response and one minor regression were observed in the studied patients; these two patients had the 175 mg/m2 dose, highest peak levels (2.4 and 2.8 micrograms/ml) and highest AUCs (197 and 228 micrograms ml-1 h).","Kinetics of metoprine, a lipid-soluble antifolate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[μg] / [ml],2.8,79321,DB00205,Pyrimethamine
,7332733,AUCs,"5 One partial response and one minor regression were observed in the studied patients; these two patients had the 175 mg/m2 dose, highest peak levels (2.4 and 2.8 micrograms/ml) and highest AUCs (197 and 228 micrograms ml-1 h).","Kinetics of metoprine, a lipid-soluble antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[h·μg] / [ml],197,79322,DB00205,Pyrimethamine
,7332733,AUCs,"5 One partial response and one minor regression were observed in the studied patients; these two patients had the 175 mg/m2 dose, highest peak levels (2.4 and 2.8 micrograms/ml) and highest AUCs (197 and 228 micrograms ml-1 h).","Kinetics of metoprine, a lipid-soluble antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),[h·μg] / [ml],228,79323,DB00205,Pyrimethamine
,7332733,Total urinary excretion,7 Total urinary excretion of dihydrofolate reductase inhibitors (as metoprine equivalents) in the first 120 h ranged from 5 to 17% of the administered dose.,"Kinetics of metoprine, a lipid-soluble antifolate. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332733/),%,5 to 17,79324,DB00205,Pyrimethamine
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],3.28,80932,DB00205,Pyrimethamine
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],8.49,80933,DB00205,Pyrimethamine
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],9.13,80934,DB00205,Pyrimethamine
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,345,80935,DB00205,Pyrimethamine
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,383,80936,DB00205,Pyrimethamine
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,428,80937,DB00205,Pyrimethamine
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,72.9,80938,DB00205,Pyrimethamine
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,31.3,80939,DB00205,Pyrimethamine
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,32.5,80940,DB00205,Pyrimethamine
,17620000,t(1/2 lambda),The t(1/2 lambda) of N-DEAQ ranged from 3 days to 12 days.,Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620000/),d,3,86764,DB00205,Pyrimethamine
,17620000,t(1/2 lambda),The t(1/2 lambda) of N-DEAQ ranged from 3 days to 12 days.,Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620000/),d,12,86765,DB00205,Pyrimethamine
,3555581,fever,"All patients responded to treatment with fever and parasite clearance times of 61 +/- 29 h (mean +/- s.d.) and 52 +/- 24 h, respectively.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,61,87380,DB00205,Pyrimethamine
,3555581,parasite clearance times,"All patients responded to treatment with fever and parasite clearance times of 61 +/- 29 h (mean +/- s.d.) and 52 +/- 24 h, respectively.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,61,87381,DB00205,Pyrimethamine
,3555581,parasite clearance times,"All patients responded to treatment with fever and parasite clearance times of 61 +/- 29 h (mean +/- s.d.) and 52 +/- 24 h, respectively.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,52,87382,DB00205,Pyrimethamine
,3555581,apparent absorption half-time (t1/2abs),The mean apparent absorption half-time (t1/2abs) of mefloquine was 4.89 h (range 2.25-9.72) and mean peak plasma concentration was 1815 ng ml-1 (range 725-3368).,Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,4.89,87383,DB00205,Pyrimethamine
,3555581,peak plasma concentration,The mean apparent absorption half-time (t1/2abs) of mefloquine was 4.89 h (range 2.25-9.72) and mean peak plasma concentration was 1815 ng ml-1 (range 725-3368).,Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],1815,87384,DB00205,Pyrimethamine
,3555581,Peak plasma mefloquine concentrations,"Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],725,87385,DB00205,Pyrimethamine
,3555581,Peak plasma mefloquine concentrations,"Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],956,87386,DB00205,Pyrimethamine
,3555581,Peak plasma mefloquine concentrations,"Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],1972,87387,DB00205,Pyrimethamine
,9241112,concentrations,"AMT can be detected in the CSF after oral administration of ZDV; concentrations of AMT in CSF ranged from 0.75 to 4.8 ng/ml (median, 1.7 ng/ml).","Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241112/),,0.75 to 4.8,88251,DB00205,Pyrimethamine
,9241112,concentrations,"AMT can be detected in the CSF after oral administration of ZDV; concentrations of AMT in CSF ranged from 0.75 to 4.8 ng/ml (median, 1.7 ng/ml).","Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241112/),ng,1.7,88252,DB00205,Pyrimethamine
,9241112,CSF-plasma concentration ratio,"The median CSF-plasma concentration ratio was 1, and equaled that for ZDV.","Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241112/),,1,88253,DB00205,Pyrimethamine
,1674024,cure rate,The cure rate at 28 days was 70.8% (95% Cl 67-77.2%).,Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1674024/),%,70.8,91765,DB00205,Pyrimethamine
,1674024,Failure rates,"Failure rates were 50% in children under 6 years old, 29% in the 6-15 age group, and 19% in adults (p less than 0.001).",Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1674024/),%,50,91766,DB00205,Pyrimethamine
,1674024,Failure rates,"Failure rates were 50% in children under 6 years old, 29% in the 6-15 age group, and 19% in adults (p less than 0.001).",Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1674024/),%,29,91767,DB00205,Pyrimethamine
,1674024,Failure rates,"Failure rates were 50% in children under 6 years old, 29% in the 6-15 age group, and 19% in adults (p less than 0.001).",Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1674024/),%,19,91768,DB00205,Pyrimethamine
,26732683,half-life,"The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively.",Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26732683/),d,12.0,92972,DB00205,Pyrimethamine
,26732683,observed clearance (CL/f),"The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively.",Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26732683/),[l] / [h·kg],0.035,92973,DB00205,Pyrimethamine
,26732683,area-under-the-curve (AUC0→∞),"The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively.",Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26732683/),[µg-h] / [ml],431,92974,DB00205,Pyrimethamine
,9080334,flow-rate,"Chromatographic separation consisted of the mobile phase (methanol-water containing 0.005 M octanesulfonic acid, 50:50, v/v) running through the column (Techopak-10 C18) at a flow-rate of 1.6 ml/min.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),[ml] / [min],1.6,95600,DB00205,Pyrimethamine
,9080334,recoveries,"The mean recoveries of PYR and QN at a concentration range of 50 and 500 ng/ml were 98.9 and 89%, and 94.7 and 96% for PYR and QN.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),%,98.9,95601,DB00205,Pyrimethamine
,9080334,recoveries,"The mean recoveries of PYR and QN at a concentration range of 50 and 500 ng/ml were 98.9 and 89%, and 94.7 and 96% for PYR and QN.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),%,89,95602,DB00205,Pyrimethamine
,9080334,recoveries,"The mean recoveries of PYR and QN at a concentration range of 50 and 500 ng/ml were 98.9 and 89%, and 94.7 and 96% for PYR and QN.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),%,94.7,95603,DB00205,Pyrimethamine
,9080334,recoveries,"The mean recoveries of PYR and QN at a concentration range of 50 and 500 ng/ml were 98.9 and 89%, and 94.7 and 96% for PYR and QN.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),%,96,95604,DB00205,Pyrimethamine
,9080334,minimum detectable concentrations,The minimum detectable concentrations for PYR and QN in plasma were 3 and 10 ng/ml.,Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),[ng] / [ml],3,95605,DB00205,Pyrimethamine
,9080334,minimum detectable concentrations,The minimum detectable concentrations for PYR and QN in plasma were 3 and 10 ng/ml.,Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),[ng] / [ml],10,95606,DB00205,Pyrimethamine
high,10774681,minimum inhibition concentration (MIC),All of the isolates exhibited high grade resistance to PYR with the minimum inhibition concentration (MIC) of as high as 10(-5) M.,"Investigations of incidence of pretreatment, drug sensitivity in vitro, and plasma levels of pyrimethamine in patients with multidrug resistant falciparum malaria following the three combination regimens of artemether/pyrimethamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774681/),M,10(-5),96245,DB00205,Pyrimethamine
,20086162,area under the plasma concentration-time curve,"Pregnant subjects had significantly lower area under the plasma concentration-time curve for both CQ (35,750 versus 47,892 microg.h/liter, P < 0.001) and DECQ (23,073 versus 41,584 microg.h/liter, P < 0.001), reflecting significant differences in elimination half-lives and in volumes of distribution and clearances relative to bioavailability.",Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086162/),[h·μg] / [l],"35,750",96813,DB00205,Pyrimethamine
,20086162,area under the plasma concentration-time curve,"Pregnant subjects had significantly lower area under the plasma concentration-time curve for both CQ (35,750 versus 47,892 microg.h/liter, P < 0.001) and DECQ (23,073 versus 41,584 microg.h/liter, P < 0.001), reflecting significant differences in elimination half-lives and in volumes of distribution and clearances relative to bioavailability.",Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086162/),[h·μg] / [l],"47,892",96814,DB00205,Pyrimethamine
,20086162,area under the plasma concentration-time curve,"Pregnant subjects had significantly lower area under the plasma concentration-time curve for both CQ (35,750 versus 47,892 microg.h/liter, P < 0.001) and DECQ (23,073 versus 41,584 microg.h/liter, P < 0.001), reflecting significant differences in elimination half-lives and in volumes of distribution and clearances relative to bioavailability.",Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086162/),[h·μg] / [l],"23,073",96815,DB00205,Pyrimethamine
,20086162,area under the plasma concentration-time curve,"Pregnant subjects had significantly lower area under the plasma concentration-time curve for both CQ (35,750 versus 47,892 microg.h/liter, P < 0.001) and DECQ (23,073 versus 41,584 microg.h/liter, P < 0.001), reflecting significant differences in elimination half-lives and in volumes of distribution and clearances relative to bioavailability.",Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086162/),[h·μg] / [l],"41,584",96816,DB00205,Pyrimethamine
,2338028,elimination half-life,"The pharmacokinetic parameters of elimination half-life, total clearance and apparent volume of distribution of M were 11 days, 45.8 ml/h.kg, and 14.8 l/kg, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),d,11,97356,DB00205,Pyrimethamine
,2338028,total clearance,"The pharmacokinetic parameters of elimination half-life, total clearance and apparent volume of distribution of M were 11 days, 45.8 ml/h.kg, and 14.8 l/kg, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),[ml] / [h·kg],45.8,97357,DB00205,Pyrimethamine
,2338028,apparent volume of distribution,"The pharmacokinetic parameters of elimination half-life, total clearance and apparent volume of distribution of M were 11 days, 45.8 ml/h.kg, and 14.8 l/kg, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),[l] / [kg],14.8,97358,DB00205,Pyrimethamine
,2338028,relative bioavailability,"The relative bioavailability of P, S, and M in the lacquered and non-lacquered tablet formulations in the 6 subjects studied were not significantly different with values (mean +/- SD) of 0.98 +/- 0.06, 1.28 +/- 0.20 and 1.02 +/- 0.17, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),,0.98,97359,DB00205,Pyrimethamine
,2338028,relative bioavailability,"The relative bioavailability of P, S, and M in the lacquered and non-lacquered tablet formulations in the 6 subjects studied were not significantly different with values (mean +/- SD) of 0.98 +/- 0.06, 1.28 +/- 0.20 and 1.02 +/- 0.17, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),,1.28,97360,DB00205,Pyrimethamine
,2338028,relative bioavailability,"The relative bioavailability of P, S, and M in the lacquered and non-lacquered tablet formulations in the 6 subjects studied were not significantly different with values (mean +/- SD) of 0.98 +/- 0.06, 1.28 +/- 0.20 and 1.02 +/- 0.17, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),,1.02,97361,DB00205,Pyrimethamine
,8256106,half-life,The mean half-life for L was 26 days.,Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8256106/),d,26,106680,DB00205,Pyrimethamine
,8256106,AUCs,The AUCs in the time interval 0-14 days for L varied between 19.3-31.5 mumol x days/l.,Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8256106/),[d·μM] / [l],19.3-31.5,106681,DB00205,Pyrimethamine
,8256106,trough concentrations,The range of trough concentrations at day 0 and 14 were 0.95-2.01 mumol/l for L and 1.69-5.62 mumol/l for the metabolite.,Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8256106/),[μM] / [l],0.95-2.01,106682,DB00205,Pyrimethamine
,8256106,trough concentrations,The range of trough concentrations at day 0 and 14 were 0.95-2.01 mumol/l for L and 1.69-5.62 mumol/l for the metabolite.,Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8256106/),[μM] / [l],1.69-5.62,106683,DB00205,Pyrimethamine
,20166435,area under the concentration-time curve (AUC),"The greatest bioavailability was observed in the 4-week-old rats: for the animals fed the low-protein diet, the area under the concentration-time curve (AUC) amounted to 593.0 and for those on the standard diet the AUC was 503.1.",Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),,593.0,109747,DB00205,Pyrimethamine
,20166435,AUC,"The greatest bioavailability was observed in the 4-week-old rats: for the animals fed the low-protein diet, the area under the concentration-time curve (AUC) amounted to 593.0 and for those on the standard diet the AUC was 503.1.",Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),,503.1,109748,DB00205,Pyrimethamine
,20166435,k(e),The k(e) values were lower in the younger rats (i.e. 0.0121 h(-1) and 0.0135 h(-1)) than in the older animals (i.e. 0.0164 h(-1) and 0.0193 h(-1) respectively).,Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),1/[h],0.0121,109749,DB00205,Pyrimethamine
,20166435,k(e),The k(e) values were lower in the younger rats (i.e. 0.0121 h(-1) and 0.0135 h(-1)) than in the older animals (i.e. 0.0164 h(-1) and 0.0193 h(-1) respectively).,Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),1/[h],0.0135,109750,DB00205,Pyrimethamine
,20166435,k(e),The k(e) values were lower in the younger rats (i.e. 0.0121 h(-1) and 0.0135 h(-1)) than in the older animals (i.e. 0.0164 h(-1) and 0.0193 h(-1) respectively).,Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),1/[h],0.0164,109751,DB00205,Pyrimethamine
,20166435,k(e),The k(e) values were lower in the younger rats (i.e. 0.0121 h(-1) and 0.0135 h(-1)) than in the older animals (i.e. 0.0164 h(-1) and 0.0193 h(-1) respectively).,Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),1/[h],0.0193,109752,DB00205,Pyrimethamine
,20166435,elimination half-life (t1/2),"The elimination half-life (t1/2) was higher in the 4-week-old rats (i.e. 57.1 h; 8% protein, and 51.2 h; 24% protein) than in the 12-week-old animals (i.e. 42.4 h; 8% protein, and 36.0 h; 24% protein).",Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),h,57.1,109753,DB00205,Pyrimethamine
,20166435,elimination half-life (t1/2),"The elimination half-life (t1/2) was higher in the 4-week-old rats (i.e. 57.1 h; 8% protein, and 51.2 h; 24% protein) than in the 12-week-old animals (i.e. 42.4 h; 8% protein, and 36.0 h; 24% protein).",Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),%,8,109754,DB00205,Pyrimethamine
,20166435,elimination half-life (t1/2),"The elimination half-life (t1/2) was higher in the 4-week-old rats (i.e. 57.1 h; 8% protein, and 51.2 h; 24% protein) than in the 12-week-old animals (i.e. 42.4 h; 8% protein, and 36.0 h; 24% protein).",Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),h,51.2,109755,DB00205,Pyrimethamine
,20166435,elimination half-life (t1/2),"The elimination half-life (t1/2) was higher in the 4-week-old rats (i.e. 57.1 h; 8% protein, and 51.2 h; 24% protein) than in the 12-week-old animals (i.e. 42.4 h; 8% protein, and 36.0 h; 24% protein).",Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),h,42.4,109756,DB00205,Pyrimethamine
,20166435,elimination half-life (t1/2),"The elimination half-life (t1/2) was higher in the 4-week-old rats (i.e. 57.1 h; 8% protein, and 51.2 h; 24% protein) than in the 12-week-old animals (i.e. 42.4 h; 8% protein, and 36.0 h; 24% protein).",Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),h,36.0,109757,DB00205,Pyrimethamine
,20166435,elimination half-life (t1/2),"The elimination half-life (t1/2) was higher in the 4-week-old rats (i.e. 57.1 h; 8% protein, and 51.2 h; 24% protein) than in the 12-week-old animals (i.e. 42.4 h; 8% protein, and 36.0 h; 24% protein).",Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166435/),%,24,109758,DB00205,Pyrimethamine
,9618735,parasite,"An oral dose of 10 mg/kg quinine dihydrochloride administered 8-hourly for 7 days gave parasite and fever clearance times of 36.0 +/- 16.6 h and 18.0 +/- 6.4 h, respectively.",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),h,36.0,110901,DB00205,Pyrimethamine
,9618735,fever clearance times,"An oral dose of 10 mg/kg quinine dihydrochloride administered 8-hourly for 7 days gave parasite and fever clearance times of 36.0 +/- 16.6 h and 18.0 +/- 6.4 h, respectively.",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),h,18.0,110902,DB00205,Pyrimethamine
,9618735,AUC(0-12),In acute malaria plasma quinine levels were more than two-fold higher than in convalescence; the mean AUC(0-12) in malaria was 37.9 +/- 14.7 micrograms.h/ml compared to 17.9 +/- 8.5 micrograms.h/ml in convalescence.,Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[h·μg] / [ml],37.9,110903,DB00205,Pyrimethamine
,9618735,AUC(0-12),In acute malaria plasma quinine levels were more than two-fold higher than in convalescence; the mean AUC(0-12) in malaria was 37.9 +/- 14.7 micrograms.h/ml compared to 17.9 +/- 8.5 micrograms.h/ml in convalescence.,Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[h·μg] / [ml],17.9,110904,DB00205,Pyrimethamine
,9618735,apparent oral clearance (CL/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[ml] / [kg·min],1.9,110905,DB00205,Pyrimethamine
,9618735,apparent oral clearance (CL/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[ml] / [kg·min],4.5,110906,DB00205,Pyrimethamine
,9618735,volume of distribution (Vd/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[l] / [kg],1.8,110907,DB00205,Pyrimethamine
,9618735,volume of distribution (Vd/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[l] / [kg],4.2,110908,DB00205,Pyrimethamine
,17922406,half-life,"Among prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed in postpartum women (148 vs 256 h; P<.001), and the median AUC(0-->infinity) was ~40% lower (22,816 vs 40,106 microg/mL/h, P<.001).",Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922406/),h,148,119708,DB00205,Pyrimethamine
,17922406,half-life,"Among prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed in postpartum women (148 vs 256 h; P<.001), and the median AUC(0-->infinity) was ~40% lower (22,816 vs 40,106 microg/mL/h, P<.001).",Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922406/),h,256,119709,DB00205,Pyrimethamine
,17922406,AUC(0-->infinity),"Among prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed in postpartum women (148 vs 256 h; P<.001), and the median AUC(0-->infinity) was ~40% lower (22,816 vs 40,106 microg/mL/h, P<.001).",Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922406/),[μg] / [h·ml],"22,816",119710,DB00205,Pyrimethamine
,17922406,AUC(0-->infinity),"Among prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed in postpartum women (148 vs 256 h; P<.001), and the median AUC(0-->infinity) was ~40% lower (22,816 vs 40,106 microg/mL/h, P<.001).",Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922406/),[μg] / [h·ml],"40,106",119711,DB00205,Pyrimethamine
,23907530,Km,"The specific uptake of thiamine was observed in MATE1-, MATE2-K- or OCT2-expressing HEK293 cells with Km of 3.5 ± 1.0, 3.9 ± 0.8 and 59.9 ± 6.7 μM, respectively.",Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907530/),μM,3.5,119937,DB00205,Pyrimethamine
,23907530,Km,"The specific uptake of thiamine was observed in MATE1-, MATE2-K- or OCT2-expressing HEK293 cells with Km of 3.5 ± 1.0, 3.9 ± 0.8 and 59.9 ± 6.7 μM, respectively.",Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907530/),μM,3.9,119938,DB00205,Pyrimethamine
,23907530,Km,"The specific uptake of thiamine was observed in MATE1-, MATE2-K- or OCT2-expressing HEK293 cells with Km of 3.5 ± 1.0, 3.9 ± 0.8 and 59.9 ± 6.7 μM, respectively.",Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907530/),μM,59.9,119939,DB00205,Pyrimethamine
,3893840,half-lives (t1/2 beta),"In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine and proguanil (chloroguanide) are all rapidly eliminated with half-lives (t1/2 beta) of between 6 and 12 hours.",Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,6 and 12,134980,DB00205,Pyrimethamine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6 to 50,134981,DB00205,Pyrimethamine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6.5 to 33,134982,DB00205,Pyrimethamine
,3893840,t1/2,"Pyrimethamine (t1/2 35 to 175 hours) has more limited tissue distribution, plasma and erythrocyte concentrations are similar, and 85% of the drug in plasma is bound to plasma proteins.",Clinical pharmacokinetics of antimalarial drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,35 to 175,134983,DB00205,Pyrimethamine
,10750517,parasite clearance time (PCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),d,two,138310,DB00205,Pyrimethamine
,10750517,fever clearance time (FCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),h,48,138311,DB00205,Pyrimethamine
,3608621,whole blood to plasma concentration ratios,"The mean whole blood to plasma concentration ratios of SULF and PYR were 0.62 and 0.87, respectively.",Pharmacokinetics of sulfadoxine and pyrimethamine after Fansidar administration in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608621/),,0.62,138637,DB00205,Pyrimethamine
,3608621,whole blood to plasma concentration ratios,"The mean whole blood to plasma concentration ratios of SULF and PYR were 0.62 and 0.87, respectively.",Pharmacokinetics of sulfadoxine and pyrimethamine after Fansidar administration in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608621/),,0,138638,DB00205,Pyrimethamine
,17967917,volume of distribution at steady state,"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [kg],431,141186,DB00205,Pyrimethamine
,17967917,bioavailability (Vss/F),"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [kg],431,141187,DB00205,Pyrimethamine
,17967917,clearance (CL/F),"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [h·kg],0.85,141188,DB00205,Pyrimethamine
,17967917,distribution half-life (t 1/2 alpha),"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,0.12,141189,DB00205,Pyrimethamine
,17967917,elimination half-life (t 1/2 beta),"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,413,141190,DB00205,Pyrimethamine
,17967917,Vss/F,"For CQ, the median Vss/F was 154 liters/kg (IQR, 101 to 210 liters/kg), the median CL/F was 0.80 liters/h/kg (IQR, 0.52 to 0.96 liters/h/kg), the median t 1/2 alpha was 0.43 h (IQR, 0.05 to 1.82 h), and the median t 1/2 beta was 233 h (IQR, 206 to 298 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [kg],154,141191,DB00205,Pyrimethamine
,17967917,CL/F,"For CQ, the median Vss/F was 154 liters/kg (IQR, 101 to 210 liters/kg), the median CL/F was 0.80 liters/h/kg (IQR, 0.52 to 0.96 liters/h/kg), the median t 1/2 alpha was 0.43 h (IQR, 0.05 to 1.82 h), and the median t 1/2 beta was 233 h (IQR, 206 to 298 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [h·kg],0.80,141192,DB00205,Pyrimethamine
,17967917,t 1/2 alpha,"For CQ, the median Vss/F was 154 liters/kg (IQR, 101 to 210 liters/kg), the median CL/F was 0.80 liters/h/kg (IQR, 0.52 to 0.96 liters/h/kg), the median t 1/2 alpha was 0.43 h (IQR, 0.05 to 1.82 h), and the median t 1/2 beta was 233 h (IQR, 206 to 298 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,0.43,141193,DB00205,Pyrimethamine
,17967917,t 1/2 beta,"For CQ, the median Vss/F was 154 liters/kg (IQR, 101 to 210 liters/kg), the median CL/F was 0.80 liters/h/kg (IQR, 0.52 to 0.96 liters/h/kg), the median t 1/2 alpha was 0.43 h (IQR, 0.05 to 1.82 h), and the median t 1/2 beta was 233 h (IQR, 206 to 298 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,233,141194,DB00205,Pyrimethamine
,17967917,t 1/2 beta,"The noncompartmentally derived median DECQ t 1/2 beta was 290 h (IQR, 236 to 368 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,290,141195,DB00205,Pyrimethamine
,34145987,terminal half-life,"Compared with the administration of gefapixant alone, concomitant dosing of gefapixant with pyrimethamine increased the total gefapixant plasma exposure (area under the plasma concentration-time curve from time 0 to infinity) by 24%, reduced gefapixant renal clearance by 30%, and increased gefapixant mean terminal half-life from 7.7 to 10.3 hours.","Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34145987/),h,7.7,155575,DB00205,Pyrimethamine
,34145987,terminal half-life,"Compared with the administration of gefapixant alone, concomitant dosing of gefapixant with pyrimethamine increased the total gefapixant plasma exposure (area under the plasma concentration-time curve from time 0 to infinity) by 24%, reduced gefapixant renal clearance by 30%, and increased gefapixant mean terminal half-life from 7.7 to 10.3 hours.","Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34145987/),h,10,155576,DB00205,Pyrimethamine
,7437265,apparent volume of distribution,The half-life of DDS was unaltered by PYR but the apparent volume of distribution was significantly increased from a mean of 1.53 1 kg-1 to 1.93 1 kg-1 and the peak DDS plasma levels measured fell by 17%.,Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437265/),[1] / [kg],1.53,157022,DB00205,Pyrimethamine
,7437265,apparent volume of distribution,The half-life of DDS was unaltered by PYR but the apparent volume of distribution was significantly increased from a mean of 1.53 1 kg-1 to 1.93 1 kg-1 and the peak DDS plasma levels measured fell by 17%.,Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437265/),[1] / [kg],1.93,157023,DB00205,Pyrimethamine
,7437265,saliva/plasma DDS,Administration of PYR with DDS significantly alters the mean saliva/plasma DDS ratio from 0.265 to 0.358 suggesting an increase in free DDS with PYR therapy.,Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437265/),,0.265,157024,DB00205,Pyrimethamine
,7437265,saliva/plasma DDS,Administration of PYR with DDS significantly alters the mean saliva/plasma DDS ratio from 0.265 to 0.358 suggesting an increase in free DDS with PYR therapy.,Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437265/),,0.358,157025,DB00205,Pyrimethamine
,7437265,ratio,Administration of PYR with DDS significantly alters the mean saliva/plasma DDS ratio from 0.265 to 0.358 suggesting an increase in free DDS with PYR therapy.,Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437265/),,0.265,157026,DB00205,Pyrimethamine
,7437265,ratio,Administration of PYR with DDS significantly alters the mean saliva/plasma DDS ratio from 0.265 to 0.358 suggesting an increase in free DDS with PYR therapy.,Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437265/),,0.358,157027,DB00205,Pyrimethamine
,2206787,maximum plasma concentration (Cmax),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[ng] / [ml],"1,134",163281,DB00205,Pyrimethamine
,2206787,maximum plasma concentration (Cmax),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[ng] / [ml],116,163282,DB00205,Pyrimethamine
,2206787,elimination half-life (t1/2),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),h,23,163283,DB00205,Pyrimethamine
,2206787,elimination half-life (t1/2),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),h,105,163284,DB00205,Pyrimethamine
,2206787,plasma clearance (CL),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[ml] / [h·kg],37.6,163285,DB00205,Pyrimethamine
,2206787,plasma clearance (CL),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[ml] / [h·kg],15.9,163286,DB00205,Pyrimethamine
,2206787,apparent volume of distribution (Vss),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[l] / [kg],1.20,163287,DB00205,Pyrimethamine
,2206787,apparent volume of distribution (Vss),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[l] / [kg],2.29,163288,DB00205,Pyrimethamine
,2206787,t1/2,The mean t1/2 of MADDS was 22 h.,Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),h,22,163289,DB00205,Pyrimethamine
,2206787,B/P ratio,MADDS had a B/P ratio of 0.69 and an E/P ratio of 0.33.,Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),,0.69,163290,DB00205,Pyrimethamine
,2206787,E/P ratio,MADDS had a B/P ratio of 0.69 and an E/P ratio of 0.33.,Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),,0.33,163291,DB00205,Pyrimethamine
,2206787,B/P,"The B/P and E/P ratios for PYR were 0.98 and 0.54, respectively.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),,0.,163292,DB00205,Pyrimethamine
,2206787,E/P ratios,"The B/P and E/P ratios for PYR were 0.98 and 0.54, respectively.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),,0.54,163293,DB00205,Pyrimethamine
,7695295,serum elimination half-lives,The serum elimination half-lives were found to be 5.2 h for sulfadiazine and 44.4 h for pyrimethamine.,Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695295/),h,5.2,163589,DB00205,Pyrimethamine
,7695295,serum elimination half-lives,The serum elimination half-lives were found to be 5.2 h for sulfadiazine and 44.4 h for pyrimethamine.,Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695295/),h,44.4,163590,DB00205,Pyrimethamine
,7695295,maximum concentration,"Sulfadiazine reached a maximum concentration in serum of 58.7 micrograms/ml, whereas a maximum concentration in serum of 0.22 micrograms/ml was found for pyrimethamine.",Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695295/),[μg] / [ml],58.7,163591,DB00205,Pyrimethamine
,7695295,maximum concentration,"Sulfadiazine reached a maximum concentration in serum of 58.7 micrograms/ml, whereas a maximum concentration in serum of 0.22 micrograms/ml was found for pyrimethamine.",Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695295/),[μg] / [ml],0.22,163592,DB00205,Pyrimethamine
,7695295,Concentrations,Concentrations in fetal serum varied from 0.05 to 0.14 micrograms/ml for pyrimethamine and from 1.0 to 5.4 micrograms/ml for sulfadiazine.,Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695295/),[μg] / [ml],0.05 to 0.14,163593,DB00205,Pyrimethamine
,7695295,Concentrations,Concentrations in fetal serum varied from 0.05 to 0.14 micrograms/ml for pyrimethamine and from 1.0 to 5.4 micrograms/ml for sulfadiazine.,Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695295/),[μg] / [ml],1.0 to 5.4,163594,DB00205,Pyrimethamine
,21936885,concentrations,"The concentrations on day 7 (that are associated with therapeutic efficacy) were similar between the SP, SP+AQ and SP+AS treatment arms for sulphadoxine (median [IQR] 35.25 [27.38-41.70], 34.95 [28.60-40.85] and 33.40 [24.63-44.05] μg/mL) and for pyrimethamine (56.75 [46.40-92.95], 58.75 [43.60-98.60] and 59.60 [42.45-86.63] ng/mL).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),[μg] / [ml],35.25,163638,DB00205,Pyrimethamine
,21936885,concentrations,"The concentrations on day 7 (that are associated with therapeutic efficacy) were similar between the SP, SP+AQ and SP+AS treatment arms for sulphadoxine (median [IQR] 35.25 [27.38-41.70], 34.95 [28.60-40.85] and 33.40 [24.63-44.05] μg/mL) and for pyrimethamine (56.75 [46.40-92.95], 58.75 [43.60-98.60] and 59.60 [42.45-86.63] ng/mL).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),[μg] / [ml],34.95,163639,DB00205,Pyrimethamine
,21936885,concentrations,"The concentrations on day 7 (that are associated with therapeutic efficacy) were similar between the SP, SP+AQ and SP+AS treatment arms for sulphadoxine (median [IQR] 35.25 [27.38-41.70], 34.95 [28.60-40.85] and 33.40 [24.63-44.05] μg/mL) and for pyrimethamine (56.75 [46.40-92.95], 58.75 [43.60-98.60] and 59.60 [42.45-86.63] ng/mL).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),[μg] / [ml],33.40,163640,DB00205,Pyrimethamine
,21936885,concentrations,"The concentrations on day 7 (that are associated with therapeutic efficacy) were similar between the SP, SP+AQ and SP+AS treatment arms for sulphadoxine (median [IQR] 35.25 [27.38-41.70], 34.95 [28.60-40.85] and 33.40 [24.63-44.05] μg/mL) and for pyrimethamine (56.75 [46.40-92.95], 58.75 [43.60-98.60] and 59.60 [42.45-86.63] ng/mL).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),[ng] / [ml],56.75,163641,DB00205,Pyrimethamine
,21936885,concentrations,"The concentrations on day 7 (that are associated with therapeutic efficacy) were similar between the SP, SP+AQ and SP+AS treatment arms for sulphadoxine (median [IQR] 35.25 [27.38-41.70], 34.95 [28.60-40.85] and 33.40 [24.63-44.05] μg/mL) and for pyrimethamine (56.75 [46.40-92.95], 58.75 [43.60-98.60] and 59.60 [42.45-86.63] ng/mL).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),[ng] / [ml],58.75,163642,DB00205,Pyrimethamine
,21936885,concentrations,"The concentrations on day 7 (that are associated with therapeutic efficacy) were similar between the SP, SP+AQ and SP+AS treatment arms for sulphadoxine (median [IQR] 35.25 [27.38-41.70], 34.95 [28.60-40.85] and 33.40 [24.63-44.05] μg/mL) and for pyrimethamine (56.75 [46.40-92.95], 58.75 [43.60-98.60] and 59.60 [42.45-86.63] ng/mL).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),[ng] / [ml],59.60,163643,DB00205,Pyrimethamine
,21936885,volumes of distribution,"There were statistically significant differences between the pyrimethamine volumes of distribution (4.65 [3.93-6.40], 4.00 [3.03-5.43] and 5.60 [4.40-7.20] L/kg; p = 0.001) and thus elimination half-life (3.26 [2.74 -3.82], 2.78 [2.24-3.65] and 4.02 [3.05-4.85] days; p < 0.001).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),[l] / [kg],4.65,163644,DB00205,Pyrimethamine
,21936885,volumes of distribution,"There were statistically significant differences between the pyrimethamine volumes of distribution (4.65 [3.93-6.40], 4.00 [3.03-5.43] and 5.60 [4.40-7.20] L/kg; p = 0.001) and thus elimination half-life (3.26 [2.74 -3.82], 2.78 [2.24-3.65] and 4.02 [3.05-4.85] days; p < 0.001).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),[l] / [kg],4.00,163645,DB00205,Pyrimethamine
,21936885,volumes of distribution,"There were statistically significant differences between the pyrimethamine volumes of distribution (4.65 [3.93-6.40], 4.00 [3.03-5.43] and 5.60 [4.40-7.20] L/kg; p = 0.001) and thus elimination half-life (3.26 [2.74 -3.82], 2.78 [2.24-3.65] and 4.02 [3.05-4.85] days; p < 0.001).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),[l] / [kg],5.60,163646,DB00205,Pyrimethamine
,21936885,elimination half-life,"There were statistically significant differences between the pyrimethamine volumes of distribution (4.65 [3.93-6.40], 4.00 [3.03-5.43] and 5.60 [4.40-7.20] L/kg; p = 0.001) and thus elimination half-life (3.26 [2.74 -3.82], 2.78 [2.24-3.65] and 4.02 [3.05-4.85] days; p < 0.001).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),d,3.26,163647,DB00205,Pyrimethamine
,21936885,elimination half-life,"There were statistically significant differences between the pyrimethamine volumes of distribution (4.65 [3.93-6.40], 4.00 [3.03-5.43] and 5.60 [4.40-7.20] L/kg; p = 0.001) and thus elimination half-life (3.26 [2.74 -3.82], 2.78 [2.24-3.65] and 4.02 [3.05-4.85] days; p < 0.001).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),d,2.78,163648,DB00205,Pyrimethamine
,21936885,elimination half-life,"There were statistically significant differences between the pyrimethamine volumes of distribution (4.65 [3.93-6.40], 4.00 [3.03-5.43] and 5.60 [4.40-7.20] L/kg; p = 0.001) and thus elimination half-life (3.26 [2.74 -3.82], 2.78 [2.24-3.65] and 4.02 [3.05-4.85] days; p < 0.001).",Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21936885/),d,4.02,163649,DB00205,Pyrimethamine
,10817730,maximum pyrimethamine concentration,"The maximum pyrimethamine concentration of 2,089+/-565 ng ml(-1) (mean +/- standard deviation) was achieved shortly after the end of the infusion; thereafter, concentrations declined in a log-linear manner, with a half-life of 140+/-31 h.",Disposition of intravenous pyrimethamine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817730/),[ng] / [ml],"2,089",168044,DB00205,Pyrimethamine
,10817730,half-life,"The maximum pyrimethamine concentration of 2,089+/-565 ng ml(-1) (mean +/- standard deviation) was achieved shortly after the end of the infusion; thereafter, concentrations declined in a log-linear manner, with a half-life of 140+/-31 h.",Disposition of intravenous pyrimethamine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817730/),h,140,168045,DB00205,Pyrimethamine
,12100441,fever clearance times,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,48,168343,DB00205,Pyrimethamine
,12100441,fever clearance times,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,33.5,168344,DB00205,Pyrimethamine
,12100441,fever clearance times,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,39,168345,DB00205,Pyrimethamine
,12100441,fever clearance times,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,24,168346,DB00205,Pyrimethamine
,12100441,PCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,48,168347,DB00205,Pyrimethamine
,12100441,PCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,39,168348,DB00205,Pyrimethamine
,12100441,FCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,33.5,168349,DB00205,Pyrimethamine
,12100441,FCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,39,168350,DB00205,Pyrimethamine
,12100441,FCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,24,168351,DB00205,Pyrimethamine
,12100441,elimination half-life (pt1/2),"The parasite elimination half-life (pt1/2) in the CQ + SP0 group was 2.5 h, significantly shorter than the CQ + SP4 group of 5.7 h (P=0.006).",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,2.5,168352,DB00205,Pyrimethamine
,12100441,elimination half-life (pt1/2),"The parasite elimination half-life (pt1/2) in the CQ + SP0 group was 2.5 h, significantly shorter than the CQ + SP4 group of 5.7 h (P=0.006).",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,5.7,168353,DB00205,Pyrimethamine
,12100441,maximum concentration (Cmax),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],285,168354,DB00205,Pyrimethamine
,12100441,area under the curve (AUC),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],2299,168355,DB00205,Pyrimethamine
,12100441,area under the curve (AUC),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,5.7,168356,DB00205,Pyrimethamine
,12100441,area under the curve (AUC),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],89,168357,DB00205,Pyrimethamine
,12100441,area under the curve (AUC),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],1845,168358,DB00205,Pyrimethamine
,12100441,elimination half-life (t1/2),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,5.7,168359,DB00205,Pyrimethamine
,12100441,elimination half-life (t1/2),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],1845,168360,DB00205,Pyrimethamine
,12100441,elimination half-life (t1/2),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,7.3,168361,DB00205,Pyrimethamine
,12100441,Cmax,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [1980·d·ml·ml·ng],283,168362,DB00205,Pyrimethamine
,12100441,Cmax,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],220,168363,DB00205,Pyrimethamine
,12100441,Cmax,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],2680,168364,DB00205,Pyrimethamine
,12100441,AUC,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,5.9,168365,DB00205,Pyrimethamine
,12100441,AUC,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],220,168366,DB00205,Pyrimethamine
,12100441,AUC,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],2680,168367,DB00205,Pyrimethamine
,12100441,t1/2,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,8.5,168368,DB00205,Pyrimethamine
,12100441,Cmax,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[μg] / [ml],169,168369,DB00205,Pyrimethamine
,12100441,AUC,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],2758,168370,DB00205,Pyrimethamine
,12100441,AUC,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],591,168371,DB00205,Pyrimethamine
,12100441,AUC,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],3029,168372,DB00205,Pyrimethamine
,12100441,t1/2,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,10.9,168373,DB00205,Pyrimethamine
,12100441,t1/2,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,2.9,168374,DB00205,Pyrimethamine
,30528339,Ki,"Trimethoprim is a more potent inhibitor of MATE2-K than MATE1 with Ki values (μM) of 0.030-0.28 and 2.4-5.9, respectively.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),μM,0.030-0.28,174947,DB00205,Pyrimethamine
,30528339,Ki,"Trimethoprim is a more potent inhibitor of MATE2-K than MATE1 with Ki values (μM) of 0.030-0.28 and 2.4-5.9, respectively.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),μM,2.4-5.9,174948,DB00205,Pyrimethamine
,30528339,Km,"Trimethoprim is a substrate of human MATE1 and MATE2-K with Km values of 2.3 ± 0.9 and 0.018 ± 0.004 μM, and mouse Mate1, but not human OCT2, mouse Oct1 and Oct2.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),μM,2.3,174949,DB00205,Pyrimethamine
,30528339,Km,"Trimethoprim is a substrate of human MATE1 and MATE2-K with Km values of 2.3 ± 0.9 and 0.018 ± 0.004 μM, and mouse Mate1, but not human OCT2, mouse Oct1 and Oct2.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),μM,0.018,174950,DB00205,Pyrimethamine
,30528339,renal clearance (CLR),Pyrimethamine significantly reduced the renal clearance (CLR) of trimethoprim (mL/min/kg) from 40.0 ± 5.1 to 20.1 ± 3.7 (p < 0.05).,Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],40.0,174951,DB00205,Pyrimethamine
,30528339,renal clearance (CLR),Pyrimethamine significantly reduced the renal clearance (CLR) of trimethoprim (mL/min/kg) from 40.0 ± 5.1 to 20.1 ± 3.7 (p < 0.05).,Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],20.1,174952,DB00205,Pyrimethamine
,30528339,CLR,"Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],25.9,174953,DB00205,Pyrimethamine
,30528339,CLR,"Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],13.5,174954,DB00205,Pyrimethamine
,30528339,CLR,"Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],8.92,174955,DB00205,Pyrimethamine
,30528339,CLR,"Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),,11.5,174956,DB00205,Pyrimethamine
,30528339,CLR,"Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),,5.17,174957,DB00205,Pyrimethamine
,30528339,CLR,"Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),,1.31,174958,DB00205,Pyrimethamine
,30528339,CLR,"Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),,0.532,174959,DB00205,Pyrimethamine
,12641404,fever subsidence times,The dosage schedule led to a rapid clinical response and reduced parasite clearance and fever subsidence times of (31.5 +/- 10.1 hours) and (31.4 +/- 11.1 hours).,Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12641404/),h,31.4,175608,DB00205,Pyrimethamine
,1155986,Initial serum concentrations,Initial serum concentrations averaged 19-9 plus or minus 2-4 (SD) mg/100 ml and decayed to 6-2 plus or minus 2-8 mg/100 ml at 14 days.,Pharmacokinetic rationale for a malarial suppressant administered once monthly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1155986/),[mg] / [100·ml],19-9,179435,DB00205,Pyrimethamine
,1155986,Initial serum concentrations,Initial serum concentrations averaged 19-9 plus or minus 2-4 (SD) mg/100 ml and decayed to 6-2 plus or minus 2-8 mg/100 ml at 14 days.,Pharmacokinetic rationale for a malarial suppressant administered once monthly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1155986/),[mg] / [100],6-2,179436,DB00205,Pyrimethamine
,1155986,Elimination half-time,Elimination half-time averaged 195 plus or minus 44 hours.,Pharmacokinetic rationale for a malarial suppressant administered once monthly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1155986/),h,195,179437,DB00205,Pyrimethamine
,26555,plasma half-lives,"The mean plasma half-lives in man are: pyrimethamine, 85 hr; metoprine, 216 hr; etoprine, 176 hr.","Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555/),h,85,182163,DB00205,Pyrimethamine
,26555,plasma half-lives,"The mean plasma half-lives in man are: pyrimethamine, 85 hr; metoprine, 216 hr; etoprine, 176 hr.","Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555/),h,216,182164,DB00205,Pyrimethamine
,26555,plasma half-lives,"The mean plasma half-lives in man are: pyrimethamine, 85 hr; metoprine, 216 hr; etoprine, 176 hr.","Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555/),h,176,182165,DB00205,Pyrimethamine
,28971610,permeability,"Whilst all inhibited OCT1, none enhanced metformin's absorptive permeability (~0.5 × 10-6 cm/sec) suggesting that DDI AUC changes are not related to absorption.","Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971610/),[cm] / [s],0.5 × 10-6,196647,DB00205,Pyrimethamine
,25963981,area under the plasma PQ concentration-time curve (AUC0-∞),"The area under the plasma PQ concentration-time curve (AUC0-∞) was lower in the pregnant patients (median [interquartile range], 23,721 μg · h/liter [21,481 to 27,951 μg · h/liter] versus 35,644 μg · h/liter [29,546 to 39,541 μg · h/liter]; P < 0.001) in association with a greater clearance relative to bioavailability (73.5 liters/h [69.4 to 78.4] versus 53.8 liters/h [49.7 to 58.2]; P < 0.001), but pregnancy did not influence the pharmacokinetics of DHA.","Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963981/),[h·μg] / [l],"23,721",196697,DB00205,Pyrimethamine
,25963981,area under the plasma PQ concentration-time curve (AUC0-∞),"The area under the plasma PQ concentration-time curve (AUC0-∞) was lower in the pregnant patients (median [interquartile range], 23,721 μg · h/liter [21,481 to 27,951 μg · h/liter] versus 35,644 μg · h/liter [29,546 to 39,541 μg · h/liter]; P < 0.001) in association with a greater clearance relative to bioavailability (73.5 liters/h [69.4 to 78.4] versus 53.8 liters/h [49.7 to 58.2]; P < 0.001), but pregnancy did not influence the pharmacokinetics of DHA.","Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963981/),[h·μg] / [l],"35,644",196698,DB00205,Pyrimethamine
,25963981,clearance relative to bioavailability,"The area under the plasma PQ concentration-time curve (AUC0-∞) was lower in the pregnant patients (median [interquartile range], 23,721 μg · h/liter [21,481 to 27,951 μg · h/liter] versus 35,644 μg · h/liter [29,546 to 39,541 μg · h/liter]; P < 0.001) in association with a greater clearance relative to bioavailability (73.5 liters/h [69.4 to 78.4] versus 53.8 liters/h [49.7 to 58.2]; P < 0.001), but pregnancy did not influence the pharmacokinetics of DHA.","Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963981/),[l] / [h],73.5,196699,DB00205,Pyrimethamine
,25963981,clearance relative to bioavailability,"The area under the plasma PQ concentration-time curve (AUC0-∞) was lower in the pregnant patients (median [interquartile range], 23,721 μg · h/liter [21,481 to 27,951 μg · h/liter] versus 35,644 μg · h/liter [29,546 to 39,541 μg · h/liter]; P < 0.001) in association with a greater clearance relative to bioavailability (73.5 liters/h [69.4 to 78.4] versus 53.8 liters/h [49.7 to 58.2]; P < 0.001), but pregnancy did not influence the pharmacokinetics of DHA.","Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963981/),[l] / [h],53.8,196700,DB00205,Pyrimethamine
,3493885,elimination half-life,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),h,123,200019,DB00205,Pyrimethamine
,3493885,elimination half-life,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),h,179,200020,DB00205,Pyrimethamine
,3493885,elimination half-life,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),h,550,200021,DB00205,Pyrimethamine
,3493885,volume of distribution,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[1] / [kg],2.5,200022,DB00205,Pyrimethamine
,3493885,volume of distribution,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[1] / [kg],0.15,200023,DB00205,Pyrimethamine
,3493885,volume of distribution,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[1] / [kg],18.6,200024,DB00205,Pyrimethamine
,3493885,total systemic clearance,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[ml] / [h·kg],14.0,200025,DB00205,Pyrimethamine
,3493885,total systemic clearance,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[ml] / [h·kg],0.64,200026,DB00205,Pyrimethamine
,3493885,total systemic clearance,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[ml] / [h·kg],24.0,200027,DB00205,Pyrimethamine
,3608626,S,"Following administration of Fansimef all three components revealed long elimination half-lives (P = 88 h, S = 183 h, M = 437 h) and high binding to plasma proteins (P = 92.5%, S = 87.6%, M = 97.6%).",Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),h,183,200145,DB00205,Pyrimethamine
,3608626,S,"Following administration of Fansimef all three components revealed long elimination half-lives (P = 88 h, S = 183 h, M = 437 h) and high binding to plasma proteins (P = 92.5%, S = 87.6%, M = 97.6%).",Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),h,437,200146,DB00205,Pyrimethamine
,3608626,apparent volume of distribution in the postdistributive phase (VD beta/F),The apparent volume of distribution in the postdistributive phase (VD beta/F) was small for S (0.13 l/kg) but amounted to 2.1 l/kg for P and reached even 11.8 l/kg in the case of M.,Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[l] / [kg],0.13,200147,DB00205,Pyrimethamine
,3608626,apparent volume of distribution in the postdistributive phase (VD beta/F),The apparent volume of distribution in the postdistributive phase (VD beta/F) was small for S (0.13 l/kg) but amounted to 2.1 l/kg for P and reached even 11.8 l/kg in the case of M.,Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[l] / [kg],2.1,200148,DB00205,Pyrimethamine
,3608626,apparent volume of distribution in the postdistributive phase (VD beta/F),The apparent volume of distribution in the postdistributive phase (VD beta/F) was small for S (0.13 l/kg) but amounted to 2.1 l/kg for P and reached even 11.8 l/kg in the case of M.,Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[l] / [kg],11.8,200149,DB00205,Pyrimethamine
,3608626,systemic clearance (ClTS/F),"The systemic clearance (ClTS/F) showed almost identical values for P and M, namely approximately equal to 19 ml/h/kg, while sulfadoxine reached only a value of 0.5 ml/h/kg.",Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[ml] / [h·kg],19,200150,DB00205,Pyrimethamine
,3608626,systemic clearance (ClTS/F),"The systemic clearance (ClTS/F) showed almost identical values for P and M, namely approximately equal to 19 ml/h/kg, while sulfadoxine reached only a value of 0.5 ml/h/kg.",Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[ml] / [h·kg],0.5,200151,DB00205,Pyrimethamine
,25963980,PQ ratio,"The population average milk:plasma PQ ratio was 0.58, with a peak of 2.5 at delivery.",Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963980/),,0.58,200349,DB00205,Pyrimethamine
,25963980,PQ ratio,"The population average milk:plasma PQ ratio was 0.58, with a peak of 2.5 at delivery.",Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963980/),,2,200350,DB00205,Pyrimethamine
,25963980,maximum milk intake,The model-derived maximum milk intake (148 ml/kg of body weight/day) was similar to the accepted value of 150 ml/kg/day.,Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963980/),[ml] / [kg],148,200351,DB00205,Pyrimethamine
,25963980,maximum milk intake,The model-derived maximum milk intake (148 ml/kg of body weight/day) was similar to the accepted value of 150 ml/kg/day.,Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963980/),[ml] / [d·kg],150,200352,DB00205,Pyrimethamine
,25963980,absolute,"Model-based simulations for PQ treatment regimens given at birth, 1 week postdelivery, and 6 weeks postdelivery showed that the highest median estimated relative total infant dose (0.36%; median absolute total dose of 101 μg/kg) was seen after maternal PQ treatment 6 weeks postpartum.",Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963980/),,101,200353,DB00205,Pyrimethamine
,18294337,failure rates,"The reported day 14 failure rates were 48% and 18%, respectively.",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),%,48,200770,DB00205,Pyrimethamine
,18294337,failure rates,"The reported day 14 failure rates were 48% and 18%, respectively.",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),%,18,200771,DB00205,Pyrimethamine
,18294337,apparent clearance (CL/F),"For CQ, the typical apparent clearance (CL/F) and volume of distribution (V(C)/F) values were estimated to be 2.84 l h(-1) and 230 l.",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),[l] / [h],2.84,200772,DB00205,Pyrimethamine
,18294337,volume of distribution (V(C)/F),"For CQ, the typical apparent clearance (CL/F) and volume of distribution (V(C)/F) values were estimated to be 2.84 l h(-1) and 230 l.",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),l,230,200773,DB00205,Pyrimethamine
,18294337,CL/F,"The typical CL/F for SDx was 0.023 l h(-1), while the factor relating its V(C)/F to normalized body weight was 1.6 l kg(-1).",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),[l] / [h],0.023,200774,DB00205,Pyrimethamine
,18294337,V(C)/F,"The typical CL/F for SDx was 0.023 l h(-1), while the factor relating its V(C)/F to normalized body weight was 1.6 l kg(-1).",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),[l] / [kg],1.6,200775,DB00205,Pyrimethamine
,2903623,half-lives,"However, in nonresponders active sulfadoxine tended to show shorter half-lives (harmonic means were 212 h vs 267 h, respectively).",Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903623/),h,212,204439,DB00205,Pyrimethamine
,2903623,half-lives,"However, in nonresponders active sulfadoxine tended to show shorter half-lives (harmonic means were 212 h vs 267 h, respectively).",Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903623/),h,267,204440,DB00205,Pyrimethamine
,29547881,venous plasma concentrations,Model-defined PQ target venous plasma concentrations of 13.9 ng/mL provided 99% protection from P. falciparum infection during pregnancy.,Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29547881/),[ng] / [ml],13.9,206564,DB00205,Pyrimethamine
,19918170,concentration,"The blood concentration profile of SDX was similar in patients whose infection responded to treatment and those who failed treatment; mean SDX concentration values were similar for day 3 (179 vs 157 μg/mL, P = 0.734), day 7 (84 vs 51 μg/mL, P = 0.365), and day 14 (50 vs 14 μg/mL, P = 0.151).",Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918170/),μ,84,208588,DB00205,Pyrimethamine
,19918170,concentration,"The blood concentration profile of SDX was similar in patients whose infection responded to treatment and those who failed treatment; mean SDX concentration values were similar for day 3 (179 vs 157 μg/mL, P = 0.734), day 7 (84 vs 51 μg/mL, P = 0.365), and day 14 (50 vs 14 μg/mL, P = 0.151).",Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918170/),μ,51,208589,DB00205,Pyrimethamine
,19918170,concentration,"The blood concentration profile of SDX was similar in patients whose infection responded to treatment and those who failed treatment; mean SDX concentration values were similar for day 3 (179 vs 157 μg/mL, P = 0.734), day 7 (84 vs 51 μg/mL, P = 0.365), and day 14 (50 vs 14 μg/mL, P = 0.151).",Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918170/),,50,208590,DB00205,Pyrimethamine
,19918170,concentration,"The blood concentration profile of SDX was similar in patients whose infection responded to treatment and those who failed treatment; mean SDX concentration values were similar for day 3 (179 vs 157 μg/mL, P = 0.734), day 7 (84 vs 51 μg/mL, P = 0.365), and day 14 (50 vs 14 μg/mL, P = 0.151).",Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918170/),,14,208591,DB00205,Pyrimethamine
,19918170,area under the curve,"Extent of exposure (area under the curve) to SDX was also similar in the patients (1196 vs 1013 μg d/mL, P = 0.561).",Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918170/),[d·μg] / [ml],1196,208592,DB00205,Pyrimethamine
,19918170,area under the curve,"Extent of exposure (area under the curve) to SDX was also similar in the patients (1196 vs 1013 μg d/mL, P = 0.561).",Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918170/),[d·μg] / [ml],1013,208593,DB00205,Pyrimethamine
,19918170,maximum concentration,"Age-stratified analysis showed that SDX concentrations were significantly higher in older children (older than 5 years); the mean maximum concentration (125 vs 295 μg/mL, P = 0.001), extent of exposure (812 vs 1562 μg d/mL, P = 0.001), day 3 concentration (98 vs 250 μg/mL, P = 0.001), and day 7 concentration (54 vs 128 μg/mL, P = 0.007) were higher.",Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918170/),[μg] / [ml],125,208594,DB00205,Pyrimethamine
,19918170,maximum concentration,"Age-stratified analysis showed that SDX concentrations were significantly higher in older children (older than 5 years); the mean maximum concentration (125 vs 295 μg/mL, P = 0.001), extent of exposure (812 vs 1562 μg d/mL, P = 0.001), day 3 concentration (98 vs 250 μg/mL, P = 0.001), and day 7 concentration (54 vs 128 μg/mL, P = 0.007) were higher.",Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918170/),[μg] / [ml],295,208595,DB00205,Pyrimethamine
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,27.2,209604,DB00205,Pyrimethamine
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,6.3,209605,DB00205,Pyrimethamine
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,28.9,209606,DB00205,Pyrimethamine
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,133.9,209607,DB00205,Pyrimethamine
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,29.1,209608,DB00205,Pyrimethamine
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,0.61,209609,DB00205,Pyrimethamine
,2868095,minimum inhibitory concentration (MIC),25% of animals dosed with BASE died; among the survivors plasma drug levels fell rapidly below the minimum inhibitory concentration (MIC) for Plasmodium berghei (100-200 ng ml-1) by 5 weeks.,The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868095/),[ng] / [ml],100-200,209654,DB00205,Pyrimethamine
,2868095,initial elimination of 14C,The rapid initial elimination of 14C-radioactivity (2.64 +/- 0.47% dose day-1 over 4 weeks) seen after dosage with [14C]BASE reflected the plasma disposition of pyrimethamine in the mice dosed with BASE.,The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868095/),[%·dose] / [d],2.64,209655,DB00205,Pyrimethamine
,2868095,Excretion,"Excretion of 14C-radioactivity after [14C]PAM was gradual and sustained with a low mean daily rate, that was maintained throughout the study i.e. 1.21 +/- 0.17% day-1 (4 weeks), 0.88 +/- 0.28% day-1 (8 weeks), 0.5 +/- 0.31% day-1 (12 weeks), 0.42 +/- 0.27% day-1 (16 weeks).",The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868095/),[%] / [d],1.21,209656,DB00205,Pyrimethamine
,2868095,Excretion,"Excretion of 14C-radioactivity after [14C]PAM was gradual and sustained with a low mean daily rate, that was maintained throughout the study i.e. 1.21 +/- 0.17% day-1 (4 weeks), 0.88 +/- 0.28% day-1 (8 weeks), 0.5 +/- 0.31% day-1 (12 weeks), 0.42 +/- 0.27% day-1 (16 weeks).",The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868095/),[%] / [d],0.88,209657,DB00205,Pyrimethamine
,2868095,Excretion,"Excretion of 14C-radioactivity after [14C]PAM was gradual and sustained with a low mean daily rate, that was maintained throughout the study i.e. 1.21 +/- 0.17% day-1 (4 weeks), 0.88 +/- 0.28% day-1 (8 weeks), 0.5 +/- 0.31% day-1 (12 weeks), 0.42 +/- 0.27% day-1 (16 weeks).",The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868095/),[%] / [d],0.5,209658,DB00205,Pyrimethamine
,2868095,Excretion,"Excretion of 14C-radioactivity after [14C]PAM was gradual and sustained with a low mean daily rate, that was maintained throughout the study i.e. 1.21 +/- 0.17% day-1 (4 weeks), 0.88 +/- 0.28% day-1 (8 weeks), 0.5 +/- 0.31% day-1 (12 weeks), 0.42 +/- 0.27% day-1 (16 weeks).",The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868095/),[%] / [d],0.42,209659,DB00205,Pyrimethamine
,1476310,volume of distribution at steady state,"The median volume of distribution at steady state after IV administration was 1,521 ml/kg and the median elimination half-time was 12.06 hours.",Pharmacokinetics of intravenously and orally administered pyrimethamine in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476310/),[ml] / [kg],"1,521",210664,DB00205,Pyrimethamine
,1476310,elimination half-time,"The median volume of distribution at steady state after IV administration was 1,521 ml/kg and the median elimination half-time was 12.06 hours.",Pharmacokinetics of intravenously and orally administered pyrimethamine in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476310/),h,12.06,210665,DB00205,Pyrimethamine
,1476310,maximal concentration,Mean plasma concentration after oral administration fluctuated between a maximal concentration of 0.18 microgram/ml and 0.09 microgram/ml (24 hours after dosing).,Pharmacokinetics of intravenously and orally administered pyrimethamine in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476310/),[μg] / [ml],0.18,210666,DB00205,Pyrimethamine
,1476310,maximal concentration,Mean plasma concentration after oral administration fluctuated between a maximal concentration of 0.18 microgram/ml and 0.09 microgram/ml (24 hours after dosing).,Pharmacokinetics of intravenously and orally administered pyrimethamine in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476310/),[μg] / [ml],0.09,210667,DB00205,Pyrimethamine
,1476310,Bioavailability,Bioavailability after oral administration was 56%.,Pharmacokinetics of intravenously and orally administered pyrimethamine in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476310/),%,56,210668,DB00205,Pyrimethamine
,11419747,extraction recovery,The mean extraction recovery of the drug from plasma was found to be 94.9%.,Determination of sulfadoxine in human blood plasma using packed-column supercritical fluid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419747/),%,94.9,212165,DB00205,Pyrimethamine
,23084093,C(max),"The mean values of sulfadoxine C(max) (183.07 and 165.15 mg/L), AUC(0-72) (11,036.52 and 10,536.78 mg/L/h), and AUC(0-168) (22,247.05 and 21,761.02 mg/L/h) were not significantly different between the test and reference formulations, respectively.",Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23084093/),[mg] / [l],183.07,213132,DB00205,Pyrimethamine
,23084093,C(max),"The mean values of sulfadoxine C(max) (183.07 and 165.15 mg/L), AUC(0-72) (11,036.52 and 10,536.78 mg/L/h), and AUC(0-168) (22,247.05 and 21,761.02 mg/L/h) were not significantly different between the test and reference formulations, respectively.",Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23084093/),[mg] / [l],165.15,213133,DB00205,Pyrimethamine
,23084093,AUC(0-72),"The mean values of sulfadoxine C(max) (183.07 and 165.15 mg/L), AUC(0-72) (11,036.52 and 10,536.78 mg/L/h), and AUC(0-168) (22,247.05 and 21,761.02 mg/L/h) were not significantly different between the test and reference formulations, respectively.",Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23084093/),[mg] / [h·l],"11,036.52",213134,DB00205,Pyrimethamine
,23084093,AUC(0-72),"The mean values of sulfadoxine C(max) (183.07 and 165.15 mg/L), AUC(0-72) (11,036.52 and 10,536.78 mg/L/h), and AUC(0-168) (22,247.05 and 21,761.02 mg/L/h) were not significantly different between the test and reference formulations, respectively.",Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23084093/),[mg] / [h·l],"10,536.78",213135,DB00205,Pyrimethamine
,23084093,AUC(0-168),"The mean values of sulfadoxine C(max) (183.07 and 165.15 mg/L), AUC(0-72) (11,036.52 and 10,536.78 mg/L/h), and AUC(0-168) (22,247.05 and 21,761.02 mg/L/h) were not significantly different between the test and reference formulations, respectively.",Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23084093/),[mg] / [h·l],"22,247.05",213136,DB00205,Pyrimethamine
,23084093,AUC(0-168),"The mean values of sulfadoxine C(max) (183.07 and 165.15 mg/L), AUC(0-72) (11,036.52 and 10,536.78 mg/L/h), and AUC(0-168) (22,247.05 and 21,761.02 mg/L/h) were not significantly different between the test and reference formulations, respectively.",Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23084093/),[mg] / [h·l],"21,761.02",213137,DB00205,Pyrimethamine
,9797245,50% inhibitory concentration,The concentrations of clindamycin in CSF were well above the 50% inhibitory concentration of 0.001 mg/liter and the parasiticidal concentration of 0.006 mg/liter.,Penetration of clindamycin and its metabolite N-demethylclindamycin into cerebrospinal fluid following intravenous infusion of clindamycin phosphate in patients with AIDS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797245/),[mg] / [l],0.001,213486,DB00205,Pyrimethamine
,7925067,AUC,"For Fansidar(Hoffman-LaRoche) the mean AUC for PM and SD were; 0.47 mghl-1 and 45.4 mghl-1, and for Falcidin(Cosmos), the mean AUC for PM and SD were; 0.49 mg hl-1 and 42.9 mghl-1 respectively.",A study of the comparative bioavailability of pyrimethamine-sulfadoxine obtained from two oral preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925067/),1/[mghl],0.47,215879,DB00205,Pyrimethamine
,7925067,AUC,"For Fansidar(Hoffman-LaRoche) the mean AUC for PM and SD were; 0.47 mghl-1 and 45.4 mghl-1, and for Falcidin(Cosmos), the mean AUC for PM and SD were; 0.49 mg hl-1 and 42.9 mghl-1 respectively.",A study of the comparative bioavailability of pyrimethamine-sulfadoxine obtained from two oral preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925067/),1/[mghl],45.4,215880,DB00205,Pyrimethamine
,7925067,AUC,"For Fansidar(Hoffman-LaRoche) the mean AUC for PM and SD were; 0.47 mghl-1 and 45.4 mghl-1, and for Falcidin(Cosmos), the mean AUC for PM and SD were; 0.49 mg hl-1 and 42.9 mghl-1 respectively.",A study of the comparative bioavailability of pyrimethamine-sulfadoxine obtained from two oral preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925067/),[mg] / [hl],0.49,215881,DB00205,Pyrimethamine
,7925067,AUC,"For Fansidar(Hoffman-LaRoche) the mean AUC for PM and SD were; 0.47 mghl-1 and 45.4 mghl-1, and for Falcidin(Cosmos), the mean AUC for PM and SD were; 0.49 mg hl-1 and 42.9 mghl-1 respectively.",A study of the comparative bioavailability of pyrimethamine-sulfadoxine obtained from two oral preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925067/),1/[mghl],42.9,215882,DB00205,Pyrimethamine
,3708123,clearance,"There was no significant difference between these three groups in the clearance (0.29 +/- 0.05, 0.30 +/- 0.03, 0.26 +/- 0.05 ml min-1), elimination half-life (4.5 +/- 0.5, 4.8 +/- 0.8, 4.9 +/- 0.5 h) and AUC (19.4 +/- 4.4, 17.3 +/- 2.2, 21.1 +/- 4.4 micrograms.h ml-1).",The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708123/),[ml] / [min],0.29,227513,DB00205,Pyrimethamine
,3708123,clearance,"There was no significant difference between these three groups in the clearance (0.29 +/- 0.05, 0.30 +/- 0.03, 0.26 +/- 0.05 ml min-1), elimination half-life (4.5 +/- 0.5, 4.8 +/- 0.8, 4.9 +/- 0.5 h) and AUC (19.4 +/- 4.4, 17.3 +/- 2.2, 21.1 +/- 4.4 micrograms.h ml-1).",The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708123/),[ml] / [min],0.30,227514,DB00205,Pyrimethamine
,3708123,clearance,"There was no significant difference between these three groups in the clearance (0.29 +/- 0.05, 0.30 +/- 0.03, 0.26 +/- 0.05 ml min-1), elimination half-life (4.5 +/- 0.5, 4.8 +/- 0.8, 4.9 +/- 0.5 h) and AUC (19.4 +/- 4.4, 17.3 +/- 2.2, 21.1 +/- 4.4 micrograms.h ml-1).",The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708123/),[ml] / [min],0.26,227515,DB00205,Pyrimethamine
,3708123,elimination half-life,"There was no significant difference between these three groups in the clearance (0.29 +/- 0.05, 0.30 +/- 0.03, 0.26 +/- 0.05 ml min-1), elimination half-life (4.5 +/- 0.5, 4.8 +/- 0.8, 4.9 +/- 0.5 h) and AUC (19.4 +/- 4.4, 17.3 +/- 2.2, 21.1 +/- 4.4 micrograms.h ml-1).",The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708123/),h,4.5,227516,DB00205,Pyrimethamine
,3708123,elimination half-life,"There was no significant difference between these three groups in the clearance (0.29 +/- 0.05, 0.30 +/- 0.03, 0.26 +/- 0.05 ml min-1), elimination half-life (4.5 +/- 0.5, 4.8 +/- 0.8, 4.9 +/- 0.5 h) and AUC (19.4 +/- 4.4, 17.3 +/- 2.2, 21.1 +/- 4.4 micrograms.h ml-1).",The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708123/),h,4.8,227517,DB00205,Pyrimethamine
,3708123,elimination half-life,"There was no significant difference between these three groups in the clearance (0.29 +/- 0.05, 0.30 +/- 0.03, 0.26 +/- 0.05 ml min-1), elimination half-life (4.5 +/- 0.5, 4.8 +/- 0.8, 4.9 +/- 0.5 h) and AUC (19.4 +/- 4.4, 17.3 +/- 2.2, 21.1 +/- 4.4 micrograms.h ml-1).",The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708123/),h,4.9,227518,DB00205,Pyrimethamine
,3708123,AUC,"There was no significant difference between these three groups in the clearance (0.29 +/- 0.05, 0.30 +/- 0.03, 0.26 +/- 0.05 ml min-1), elimination half-life (4.5 +/- 0.5, 4.8 +/- 0.8, 4.9 +/- 0.5 h) and AUC (19.4 +/- 4.4, 17.3 +/- 2.2, 21.1 +/- 4.4 micrograms.h ml-1).",The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708123/),[h·μg] / [ml],19.4,227519,DB00205,Pyrimethamine
,3708123,AUC,"There was no significant difference between these three groups in the clearance (0.29 +/- 0.05, 0.30 +/- 0.03, 0.26 +/- 0.05 ml min-1), elimination half-life (4.5 +/- 0.5, 4.8 +/- 0.8, 4.9 +/- 0.5 h) and AUC (19.4 +/- 4.4, 17.3 +/- 2.2, 21.1 +/- 4.4 micrograms.h ml-1).",The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708123/),[h·μg] / [ml],17.3,227520,DB00205,Pyrimethamine
,3708123,AUC,"There was no significant difference between these three groups in the clearance (0.29 +/- 0.05, 0.30 +/- 0.03, 0.26 +/- 0.05 ml min-1), elimination half-life (4.5 +/- 0.5, 4.8 +/- 0.8, 4.9 +/- 0.5 h) and AUC (19.4 +/- 4.4, 17.3 +/- 2.2, 21.1 +/- 4.4 micrograms.h ml-1).",The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708123/),[h·μg] / [ml],21.1,227521,DB00205,Pyrimethamine
,8600759,50% inhibitory concentration (IC50),"The 50% inhibitory concentration (IC50) of epiroprim for T. gondii dihydrofolate reductase was 0.9 micromole, similar to that of pyrimethamine, but epiroprim was 650-fold more selective than pyrimethamine for T. gondii compared with human dihydrofolate reductase.","Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600759/),μmole,0.9,233336,DB00205,Pyrimethamine
,3495440,peak concentrations,There was considerable interindividual variability in the pharmacokinetic parameters; for example in the male subjects receiving MQ alone peak concentrations ranged between 638 and 2494 ng X ml-1 with a mean concentration of 1442 ng X ml-1.,The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3495440/),[ng] / [ml],638 and 2494,239273,DB00205,Pyrimethamine
,3495440,peak concentrations,There was considerable interindividual variability in the pharmacokinetic parameters; for example in the male subjects receiving MQ alone peak concentrations ranged between 638 and 2494 ng X ml-1 with a mean concentration of 1442 ng X ml-1.,The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3495440/),ng,144,239274,DB00205,Pyrimethamine
,19620325,area under the concentration-time curve from 0 to infinity,"Pregnancy was associated with a significantly lower area under the concentration-time curve from 0 to infinity for SDOX (22,315 versus 33,284 mg x h/liter), NASDOX (801 versus 1,590 mg x h/liter), and PYR (72,115 versus 106,065 microg x h/liter; P < 0.001 in each case).",Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620325/),[h·mg] / [l],"22,315",241749,DB00205,Pyrimethamine
,19620325,area under the concentration-time curve from 0 to infinity,"Pregnancy was associated with a significantly lower area under the concentration-time curve from 0 to infinity for SDOX (22,315 versus 33,284 mg x h/liter), NASDOX (801 versus 1,590 mg x h/liter), and PYR (72,115 versus 106,065 microg x h/liter; P < 0.001 in each case).",Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620325/),[h·mg] / [l],"33,284",241750,DB00205,Pyrimethamine
,19620325,area under the concentration-time curve from 0 to infinity,"Pregnancy was associated with a significantly lower area under the concentration-time curve from 0 to infinity for SDOX (22,315 versus 33,284 mg x h/liter), NASDOX (801 versus 1,590 mg x h/liter), and PYR (72,115 versus 106,065 microg x h/liter; P < 0.001 in each case).",Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620325/),[h·mg] / [l],801,241751,DB00205,Pyrimethamine
,19620325,area under the concentration-time curve from 0 to infinity,"Pregnancy was associated with a significantly lower area under the concentration-time curve from 0 to infinity for SDOX (22,315 versus 33,284 mg x h/liter), NASDOX (801 versus 1,590 mg x h/liter), and PYR (72,115 versus 106,065 microg x h/liter; P < 0.001 in each case).",Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620325/),[h·mg] / [l],"1,590",241752,DB00205,Pyrimethamine
,19620325,area under the concentration-time curve from 0 to infinity,"Pregnancy was associated with a significantly lower area under the concentration-time curve from 0 to infinity for SDOX (22,315 versus 33,284 mg x h/liter), NASDOX (801 versus 1,590 mg x h/liter), and PYR (72,115 versus 106,065 microg x h/liter; P < 0.001 in each case).",Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620325/),[h·μg] / [l],"72,115",241753,DB00205,Pyrimethamine
,19620325,area under the concentration-time curve from 0 to infinity,"Pregnancy was associated with a significantly lower area under the concentration-time curve from 0 to infinity for SDOX (22,315 versus 33,284 mg x h/liter), NASDOX (801 versus 1,590 mg x h/liter), and PYR (72,115 versus 106,065 microg x h/liter; P < 0.001 in each case).",Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620325/),[h·μg] / [l],"106,065",241754,DB00205,Pyrimethamine
,8726001,area under the 24-h concentration-time curve,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),[h·μg] / [ml],42.7,256619,DB00205,Pyrimethamine
,8726001,halflife,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),h,139,256620,DB00205,Pyrimethamine
,8726001,clearance,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),[l] / [h],1.28,256621,DB00205,Pyrimethamine
,8726001,volume of distribution,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),,246,256622,DB00205,Pyrimethamine
,8726001,absorption rate constant,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),[l] / [h],1.5,256623,DB00205,Pyrimethamine
,16916298,ka,"Sulfadoxine in Homapak was more rapidly absorbed (ka = 0.55 h(-1)) than in Fansidar + CQ (ka = 0.27 h(-1), p=0.004), but not more than S in Fansidar alone group (ka = 0.32 h(-1), p=0.03).","Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16916298/),1/[h],0.55,259478,DB00205,Pyrimethamine
,16916298,ka,"Sulfadoxine in Homapak was more rapidly absorbed (ka = 0.55 h(-1)) than in Fansidar + CQ (ka = 0.27 h(-1), p=0.004), but not more than S in Fansidar alone group (ka = 0.32 h(-1), p=0.03).","Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16916298/),1/[h],0.27,259479,DB00205,Pyrimethamine
,16916298,ka,"Sulfadoxine in Homapak was more rapidly absorbed (ka = 0.55 h(-1)) than in Fansidar + CQ (ka = 0.27 h(-1), p=0.004), but not more than S in Fansidar alone group (ka = 0.32 h(-1), p=0.03).","Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16916298/),1/[h],0.32,259480,DB00205,Pyrimethamine
,17178260,AUC,"After adjustment for dose, the area under the concentration-time curves (AUCs) of sulfadoxine and pyrimethamine in children aged 2 to 5 years were half of those in adults (median AUC, 410 microg/mL x d [interquartile range (IQR), 126-705 microg/mL x d] versus 816 microg/mL x d [IQR, 536-1150 microg/mL x d] [P = .0001] for sulfadoxine and 620 ng/mL x d [IQR, 229-1399 ng/mL x d] versus 1518 ng/mL x d [IQR, 1117-2013 ng/mL x d] for pyrimethamine).",Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178260/),[μg] / [d·ml],410,259806,DB00205,Pyrimethamine
,17178260,AUC,"After adjustment for dose, the area under the concentration-time curves (AUCs) of sulfadoxine and pyrimethamine in children aged 2 to 5 years were half of those in adults (median AUC, 410 microg/mL x d [interquartile range (IQR), 126-705 microg/mL x d] versus 816 microg/mL x d [IQR, 536-1150 microg/mL x d] [P = .0001] for sulfadoxine and 620 ng/mL x d [IQR, 229-1399 ng/mL x d] versus 1518 ng/mL x d [IQR, 1117-2013 ng/mL x d] for pyrimethamine).",Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178260/),[μg] / [d·ml],816,259807,DB00205,Pyrimethamine
,17178260,AUC,"After adjustment for dose, the area under the concentration-time curves (AUCs) of sulfadoxine and pyrimethamine in children aged 2 to 5 years were half of those in adults (median AUC, 410 microg/mL x d [interquartile range (IQR), 126-705 microg/mL x d] versus 816 microg/mL x d [IQR, 536-1150 microg/mL x d] [P = .0001] for sulfadoxine and 620 ng/mL x d [IQR, 229-1399 ng/mL x d] versus 1518 ng/mL x d [IQR, 1117-2013 ng/mL x d] for pyrimethamine).",Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178260/),[ng] / [d·ml],620,259808,DB00205,Pyrimethamine
,17178260,AUC,"After adjustment for dose, the area under the concentration-time curves (AUCs) of sulfadoxine and pyrimethamine in children aged 2 to 5 years were half of those in adults (median AUC, 410 microg/mL x d [interquartile range (IQR), 126-705 microg/mL x d] versus 816 microg/mL x d [IQR, 536-1150 microg/mL x d] [P = .0001] for sulfadoxine and 620 ng/mL x d [IQR, 229-1399 ng/mL x d] versus 1518 ng/mL x d [IQR, 1117-2013 ng/mL x d] for pyrimethamine).",Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178260/),[ng] / [d·ml],1518,259809,DB00205,Pyrimethamine
,17178260,clearance,"The effect of age on the AUC of sulfadoxine and pyrimethamine reflected higher clearance rates and larger apparent volumes of distribution in children aged 2 to 5 years when compared with adults (median clearance, 64.5 mL x kg(-1) x d(-1) [IQR, 46.2-132.6 mL x kg(-1) x d(-1)] versus 32.7 mL x kg(-1) x d(-1) [IQR, 22.3-52.2 mL x kg(-1) x d(-1)] for sulfadoxine [P = .0001] and 1.77 L x kg(-1) x d(-1) [IQR, 1.0-3.0 L x kg(-1) x d(-1)] versus 0.85 L x kg(-1) x d(-1) [IQR, 0.62-1.21 L x kg(-1) x d(-1)] for pyrimethamine [P = .0001]; median volume of distribution, 413 mL/kg [IQR, 299-711 mL/kg] versus 372 mL/kg [IQR, 267-488 mL/kg] for sulfadoxine [P = .0021] and 6.28 L/kg [IQR, 3.83-11.24 L/kg] versus 3.83 L/kg [IQR, 2.73-5.11 L/kg] for pyrimethamine [P = .0001]).",Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178260/),[ml] / [d·kg],64.5,259810,DB00205,Pyrimethamine
,17178260,clearance,"The effect of age on the AUC of sulfadoxine and pyrimethamine reflected higher clearance rates and larger apparent volumes of distribution in children aged 2 to 5 years when compared with adults (median clearance, 64.5 mL x kg(-1) x d(-1) [IQR, 46.2-132.6 mL x kg(-1) x d(-1)] versus 32.7 mL x kg(-1) x d(-1) [IQR, 22.3-52.2 mL x kg(-1) x d(-1)] for sulfadoxine [P = .0001] and 1.77 L x kg(-1) x d(-1) [IQR, 1.0-3.0 L x kg(-1) x d(-1)] versus 0.85 L x kg(-1) x d(-1) [IQR, 0.62-1.21 L x kg(-1) x d(-1)] for pyrimethamine [P = .0001]; median volume of distribution, 413 mL/kg [IQR, 299-711 mL/kg] versus 372 mL/kg [IQR, 267-488 mL/kg] for sulfadoxine [P = .0021] and 6.28 L/kg [IQR, 3.83-11.24 L/kg] versus 3.83 L/kg [IQR, 2.73-5.11 L/kg] for pyrimethamine [P = .0001]).",Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178260/),[ml] / [d·kg],32.7,259811,DB00205,Pyrimethamine
,17178260,clearance,"The effect of age on the AUC of sulfadoxine and pyrimethamine reflected higher clearance rates and larger apparent volumes of distribution in children aged 2 to 5 years when compared with adults (median clearance, 64.5 mL x kg(-1) x d(-1) [IQR, 46.2-132.6 mL x kg(-1) x d(-1)] versus 32.7 mL x kg(-1) x d(-1) [IQR, 22.3-52.2 mL x kg(-1) x d(-1)] for sulfadoxine [P = .0001] and 1.77 L x kg(-1) x d(-1) [IQR, 1.0-3.0 L x kg(-1) x d(-1)] versus 0.85 L x kg(-1) x d(-1) [IQR, 0.62-1.21 L x kg(-1) x d(-1)] for pyrimethamine [P = .0001]; median volume of distribution, 413 mL/kg [IQR, 299-711 mL/kg] versus 372 mL/kg [IQR, 267-488 mL/kg] for sulfadoxine [P = .0021] and 6.28 L/kg [IQR, 3.83-11.24 L/kg] versus 3.83 L/kg [IQR, 2.73-5.11 L/kg] for pyrimethamine [P = .0001]).",Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178260/),[l] / [d·kg],1.77,259812,DB00205,Pyrimethamine
,17178260,clearance,"The effect of age on the AUC of sulfadoxine and pyrimethamine reflected higher clearance rates and larger apparent volumes of distribution in children aged 2 to 5 years when compared with adults (median clearance, 64.5 mL x kg(-1) x d(-1) [IQR, 46.2-132.6 mL x kg(-1) x d(-1)] versus 32.7 mL x kg(-1) x d(-1) [IQR, 22.3-52.2 mL x kg(-1) x d(-1)] for sulfadoxine [P = .0001] and 1.77 L x kg(-1) x d(-1) [IQR, 1.0-3.0 L x kg(-1) x d(-1)] versus 0.85 L x kg(-1) x d(-1) [IQR, 0.62-1.21 L x kg(-1) x d(-1)] for pyrimethamine [P = .0001]; median volume of distribution, 413 mL/kg [IQR, 299-711 mL/kg] versus 372 mL/kg [IQR, 267-488 mL/kg] for sulfadoxine [P = .0021] and 6.28 L/kg [IQR, 3.83-11.24 L/kg] versus 3.83 L/kg [IQR, 2.73-5.11 L/kg] for pyrimethamine [P = .0001]).",Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178260/),[l] / [d·kg],0.85,259813,DB00205,Pyrimethamine
,17178260,volume of distribution,"The effect of age on the AUC of sulfadoxine and pyrimethamine reflected higher clearance rates and larger apparent volumes of distribution in children aged 2 to 5 years when compared with adults (median clearance, 64.5 mL x kg(-1) x d(-1) [IQR, 46.2-132.6 mL x kg(-1) x d(-1)] versus 32.7 mL x kg(-1) x d(-1) [IQR, 22.3-52.2 mL x kg(-1) x d(-1)] for sulfadoxine [P = .0001] and 1.77 L x kg(-1) x d(-1) [IQR, 1.0-3.0 L x kg(-1) x d(-1)] versus 0.85 L x kg(-1) x d(-1) [IQR, 0.62-1.21 L x kg(-1) x d(-1)] for pyrimethamine [P = .0001]; median volume of distribution, 413 mL/kg [IQR, 299-711 mL/kg] versus 372 mL/kg [IQR, 267-488 mL/kg] for sulfadoxine [P = .0021] and 6.28 L/kg [IQR, 3.83-11.24 L/kg] versus 3.83 L/kg [IQR, 2.73-5.11 L/kg] for pyrimethamine [P = .0001]).",Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178260/),,413,259814,DB00205,Pyrimethamine
less,21914160,half-life,"Intravenous AS is associated with high initial AS concentrations which subsequently decline rapidly, with typical AS half-life estimates of less than 15 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,15,260913,DB00205,Pyrimethamine
,21914160,clearance,"AS clearance and volume estimates average 2 - 3 L/kg/hr and 0.1 - 0.3 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [h·kg],2 - 3,260914,DB00205,Pyrimethamine
,21914160,volume,"AS clearance and volume estimates average 2 - 3 L/kg/hr and 0.1 - 0.3 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [kg],0.1 - 0.3,260915,DB00205,Pyrimethamine
,21914160,half-life,"DHA concentrations peak within 25 minutes post-dose, and DHA is eliminated with a half-life of 30 - 60 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,30 - 60,260916,DB00205,Pyrimethamine
,21914160,clearance,"DHA clearance and volume average between 0.5 - 1.5 L/kg/hr and 0.5 - 1.0 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [h·kg],0.5 - 1.5,260917,DB00205,Pyrimethamine
,21914160,volume,"DHA clearance and volume average between 0.5 - 1.5 L/kg/hr and 0.5 - 1.0 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [kg],0.5 - 1.0,260918,DB00205,Pyrimethamine
>,21914160,bioavailability,"Compared to IV administration, IM administration produces lower peaks, longer half-life values, and higher volumes of distribution for AS, as well as delayed peaks for DHA; other parameters are generally similar due to the high bioavailability, assessed by exposure to DHA, associated with IM AS administration (> 86%).","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),%,86,260919,DB00205,Pyrimethamine
>,21914160,bioavailability,Similarly high bioavailability of DHA (> 80%) is associated with oral administration.,"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),%,80,260920,DB00205,Pyrimethamine
,21914160,half-life,"Following oral AS, peak AS concentrations (Cmax) are achieved within one hour, and AS is eliminated with a half-life of 20 - 45 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,20 - 45,260921,DB00205,Pyrimethamine
,21914160,half-life,DHA Cmax values are observed within two hours post-dose; DHA half-life values average 0.5 - 1.5 hours.,"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),h,0.5 - 1.5,260922,DB00205,Pyrimethamine
,15388436,absorption rate constants,"Mean absorption rate constants, volumes of distribution, elimination rate constants, and half-lives were 0.915 h(-1), 4.379 liters/kg, 0.00839 h(-1), and 5.5 days for PYR and 1.659 h(-1), 0.392 liters/kg, 0.00526 h(-1), and 6.6 days for SDX, respectively.",Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388436/),1/[h],0.915,261277,DB00205,Pyrimethamine
,15388436,elimination rate constants,"Mean absorption rate constants, volumes of distribution, elimination rate constants, and half-lives were 0.915 h(-1), 4.379 liters/kg, 0.00839 h(-1), and 5.5 days for PYR and 1.659 h(-1), 0.392 liters/kg, 0.00526 h(-1), and 6.6 days for SDX, respectively.",Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388436/),[l] / [kg],4.379,261278,DB00205,Pyrimethamine
,15388436,half-lives,"Mean absorption rate constants, volumes of distribution, elimination rate constants, and half-lives were 0.915 h(-1), 4.379 liters/kg, 0.00839 h(-1), and 5.5 days for PYR and 1.659 h(-1), 0.392 liters/kg, 0.00526 h(-1), and 6.6 days for SDX, respectively.",Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388436/),d,5.5,261279,DB00205,Pyrimethamine
,15388436,half-lives,"Mean absorption rate constants, volumes of distribution, elimination rate constants, and half-lives were 0.915 h(-1), 4.379 liters/kg, 0.00839 h(-1), and 5.5 days for PYR and 1.659 h(-1), 0.392 liters/kg, 0.00526 h(-1), and 6.6 days for SDX, respectively.",Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388436/),d,6.6,261280,DB00205,Pyrimethamine
,24487120,renal clearance,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],18.1,271646,DB00205,Pyrimethamine
,24487120,renal clearance,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],7.60,271647,DB00205,Pyrimethamine
,24487120,CL,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],18.1,271648,DB00205,Pyrimethamine
,24487120,CL,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],7.60,271649,DB00205,Pyrimethamine
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],231,271650,DB00205,Pyrimethamine
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],135,271651,DB00205,Pyrimethamine
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],225,271652,DB00205,Pyrimethamine
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],141,271653,DB00205,Pyrimethamine
,17333157,C(max),"The C(max) of SDX were 92.9 and 98.9 microg/ml for the SP and SP+AT arms, respectively; for PYR, these were 0.86 and 0.79 microg/ml, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),[μg] / [ml],92.9,271811,DB00205,Pyrimethamine
,17333157,C(max),"The C(max) of SDX were 92.9 and 98.9 microg/ml for the SP and SP+AT arms, respectively; for PYR, these were 0.86 and 0.79 microg/ml, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),[μg] / [ml],98.9,271812,DB00205,Pyrimethamine
,17333157,C(max),"The C(max) of SDX were 92.9 and 98.9 microg/ml for the SP and SP+AT arms, respectively; for PYR, these were 0.86 and 0.79 microg/ml, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),[μg] / [ml],0.86,271813,DB00205,Pyrimethamine
,17333157,C(max),"The C(max) of SDX were 92.9 and 98.9 microg/ml for the SP and SP+AT arms, respectively; for PYR, these were 0.86 and 0.79 microg/ml, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),[μg] / [ml],0.79,271814,DB00205,Pyrimethamine
,17333157,T(max),"The T(max) of SDX were 10 and 8 h for the SP and SP+AT arms, respectively; for PYR, these were 4.0 and 3.0 h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),h,10,271815,DB00205,Pyrimethamine
,17333157,T(max),"The T(max) of SDX were 10 and 8 h for the SP and SP+AT arms, respectively; for PYR, these were 4.0 and 3.0 h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),h,8,271816,DB00205,Pyrimethamine
,17333157,T(max),"The T(max) of SDX were 10 and 8 h for the SP and SP+AT arms, respectively; for PYR, these were 4.0 and 3.0 h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),h,4.0,271817,DB00205,Pyrimethamine
,17333157,T(max),"The T(max) of SDX were 10 and 8 h for the SP and SP+AT arms, respectively; for PYR, these were 4.0 and 3.0 h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),h,3.0,271818,DB00205,Pyrimethamine
,17333157,AUC(0-288),"The AUC(0-288) of SDX were 15,840 and 18,876 microg/ml h for the SP and SP+AT arms, respectively; for PYR, they were 124 and 112 microg/ml h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),[μg] / [h·ml],"15,840",271819,DB00205,Pyrimethamine
,17333157,AUC(0-288),"The AUC(0-288) of SDX were 15,840 and 18,876 microg/ml h for the SP and SP+AT arms, respectively; for PYR, they were 124 and 112 microg/ml h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),[μg] / [h·ml],"18,876",271820,DB00205,Pyrimethamine
,17333157,AUC(0-288),"The AUC(0-288) of SDX were 15,840 and 18,876 microg/ml h for the SP and SP+AT arms, respectively; for PYR, they were 124 and 112 microg/ml h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),[μg] / [h·ml],124,271821,DB00205,Pyrimethamine
,17333157,AUC(0-288),"The AUC(0-288) of SDX were 15,840 and 18,876 microg/ml h for the SP and SP+AT arms, respectively; for PYR, they were 124 and 112 microg/ml h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),[μg] / [h·ml],112,271822,DB00205,Pyrimethamine
,17333157,t ((1/2)),"The t ((1/2)) of values for SDX were 165 and 180 h for the SP and SP+AT arms, respectively; for PYR, these were 158 and 177 h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),h,165,271823,DB00205,Pyrimethamine
,17333157,t ((1/2)),"The t ((1/2)) of values for SDX were 165 and 180 h for the SP and SP+AT arms, respectively; for PYR, these were 158 and 177 h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),h,180,271824,DB00205,Pyrimethamine
,17333157,t ((1/2)),"The t ((1/2)) of values for SDX were 165 and 180 h for the SP and SP+AT arms, respectively; for PYR, these were 158 and 177 h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),h,158,271825,DB00205,Pyrimethamine
,17333157,t ((1/2)),"The t ((1/2)) of values for SDX were 165 and 180 h for the SP and SP+AT arms, respectively; for PYR, these were 158 and 177 h, respectively.",Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333157/),h,177,271826,DB00205,Pyrimethamine
,25331702,50% inhibitory concentrations (IC50s),"4-(tert-Butyl)-2-((tert-butylamino)methyl)-6-(6-(trifluoromethyl)pyridin-3-yl)-phenol (JPC-2997) is a new aminomethylphenol compound that is highly active in vitro against the chloroquine-sensitive D6, the chloroquine-resistant W2, and the multidrug-resistant TM90-C2B Plasmodium falciparum lines, with 50% inhibitory concentrations (IC50s) ranging from 7 nM to 34 nM.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),nM,7,272496,DB00205,Pyrimethamine
,25331702,50% inhibitory concentrations (IC50s),"4-(tert-Butyl)-2-((tert-butylamino)methyl)-6-(6-(trifluoromethyl)pyridin-3-yl)-phenol (JPC-2997) is a new aminomethylphenol compound that is highly active in vitro against the chloroquine-sensitive D6, the chloroquine-resistant W2, and the multidrug-resistant TM90-C2B Plasmodium falciparum lines, with 50% inhibitory concentrations (IC50s) ranging from 7 nM to 34 nM.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),nM,34,272497,DB00205,Pyrimethamine
>,25331702,IC50s,"JPC-2997 is >2,500 times less cytotoxic (IC50s > 35 μM) to human (HepG2 and HEK293) and rodent (BHK) cell lines than the D6 parasite line.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),μM,35,272498,DB00205,Pyrimethamine
,25331702,50% effective dose (ED50),"The compound possesses potent in vivo suppression activity against Plasmodium berghei, with a 50% effective dose (ED50) of 0.5 mg/kg of body weight/day following oral dosing in the Peters 4-day test.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),[mg] / [kg],0.5,272499,DB00205,Pyrimethamine
,25331702,clearance,"Preliminary studies of JPC-2997 in mice show linear pharmacokinetics over the range 2.5 to 40 mg/kg, a low clearance of 0.22 liters/h/kg, a volume of distribution of 15.6 liters/kg, and an elimination half-life of 49.8 h.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),[l] / [h·kg],0.22,272500,DB00205,Pyrimethamine
,25331702,volume of distribution,"Preliminary studies of JPC-2997 in mice show linear pharmacokinetics over the range 2.5 to 40 mg/kg, a low clearance of 0.22 liters/h/kg, a volume of distribution of 15.6 liters/kg, and an elimination half-life of 49.8 h.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),[l] / [kg],15.6,272501,DB00205,Pyrimethamine
,25331702,elimination half-life,"Preliminary studies of JPC-2997 in mice show linear pharmacokinetics over the range 2.5 to 40 mg/kg, a low clearance of 0.22 liters/h/kg, a volume of distribution of 15.6 liters/kg, and an elimination half-life of 49.8 h.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),h,49.8,272502,DB00205,Pyrimethamine
,33556040,time to positive parasitemia,"With placebo, all six participants became parasitemic (geometric mean time to positive parasitemia 10.6 days [90% CI: 9.9-11.4]).","Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33556040/),d,10.6,272557,DB00205,Pyrimethamine
